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HSPB5 (aka αB-crystallin or CRYAB) is a small molecular weight heat shock protein 
that functions as a key chaperone in striated muscle. Mutations in HSPB5 are linked with human 
disease including cardiomyopathy, skeletal myopathy, and cataracts. Abnormal accumulation or 
protein aggregation including the mutant form of HSPB5 in muscle is a hallmark of the majority 
of known disease-associated HSPB5 variants, though it is yet unclear mechanistically how this 
mutant chaperone contributes to myopathy (reviewed in Chapter 1). This dissertation focuses on 
molecular studies of one such mutation, 343delT, which is associated with severe early-onset 
skeletal myopathy requiring ventilation to sustain life. Induced pluripotent stem cells (iPSCs) 
derived from the patient harboring the 343delT mutation along with genome edited isogenic 
control cell lines are utilized in this work as a mechanism to study the endogenous form of the 
protein in cell types of interest (i.e., skeletal and cardiac muscle). Molecular studies of 343delT 
HSPB5 demonstrate extreme insolubility of the mutant protein and suggest a loss of function 
mechanism for disease, though gain-of-toxic function cannot be excluded (Chapter 3). Chapter 2 
is included as an addendum to the Introduction on HSPB5 (Chapter 1) to provide relevant 
background information on iPSCs and genome editing. The fast-paced genome editing field is 
currently hampered by inefficient means of isolating cells containing modifications of interest. 
Previously published approaches employed in Chapter 3 were highly efficient, though required a 
two-step editing process and were not readily scalable. Chapter 4 presents a strategy for genome 
editing, termed cotargeting with selection (CTS) that involves simultaneous targeting of two loci, 
where selection for incorporation of a selection cassette into a safe-harbor locus enriches many 
fold for a separate modification at a gene of interest. CTS streamlines the genome editing process 
iv 
 
compared with previous techniques. Chapter 5 of this dissertation includes a combined discussion 
and Chapter 6 presents future experiments planned for the study of 343delT HSPB5. Altogether, 
this dissertation affords molecular insights into myopathy causing 343delT HSPB5 using cutting 
edge technology of iPSCs and genome editing, as well as providing technical advancement to the 
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INTRODUCTION ADDENDUM: INDUCED PLURIPOTENT  
 
STEM CELLS AND GENOME EDITING 
 
 
Two major technological advances in the last ten years have revolutionized the ability for 
researchers to study disease in vitro using human cells while simultaneously accelerating and 
expanding the prospects of transplantation therapy (Figure 2.1). The first advance being the 
advent of induced pluripotent stem cells (iPSCs) by the lab of 2012 Nobel Prize winner, Shinya 
Yamanaka (Takahashi and Yamanaka, 2006), providing the ability to generate patient-specific 
pluripotent stem cells from somatic cells. The second, concurrent advance is the vast 
improvements in the efficiency of genome editing allowing specific, user-defined modification of 
the genome. Both advances have surpassed critical hurdles quickly bringing the use of this system 
into everyday practice for a multitude of laboratories. As alluded to in the Introduction (Chapter 
1), iPSCs offer utility in the study of mutations in αB-crystallin (or HSPB5). Indeed, among the 
many diseases studied exploiting iPSCs to date (Tiscornia et al., 2011), the Benjamin Laboratory 
has generated both murine and human iPSC model systems for the study of mutant forms of 
HSPB5 (Limphong et al., 2013; Mitzelfelt et al., 2016) (Chapter 3). This chapter acts as an 
addendum to the introduction (Chapter 1) providing background information with regards to 
iPSCs and genome editing. 
 
Embryonic Stem Cells: A Brief History 
 Mouse embryonic stem cells (mESCs), derived from the inner cell mass of the blastocyst, 






Figure 2.1 Schematic representation of combined iPSC and genome editing 
applications. Somatic cells (e.g., fibroblasts, peripheral blood mononuclear cells (PBMCs), 
cells isolated from urine, etc.) from patients with a mutation (Mut) or unaffected individuals 
with a wildtype locus (WT) can be reprogrammed into iPSCs using reprogramming factors 
(e.g., OCT4, SOX2, KLF4, MYC, NANOG, LIN28) through delivery methods such as 
virus, mRNA, or protein for generating founding iPSC lines. Genome editing can be 
performed on founding iPSC lines to generate knock-in (KI) cell lines in either direction 
(from WT to Mut or from Mut to WT) by inserting or correcting the mutation of interest to 
generate isogenic cell lines differing only at a specified location. Additionally, knockout 
(KO) of a gene of interest can also be performed. Differentiation of founding and gene 
edited iPSC lines into cell types of interest (e.g., neurons, muscle, blood cells, fibroblasts, 
liver cells, etc.) provides a platform for in vitro disease modeling, drug screening, and 






human ESCs (hESCs) was not accomplished until 17 years later (Thomson et al., 1998). The 
defining characteristics of mammalian ESCs, unlimited self-renewal and pluripotency, made them 
uniquely attractive as a model for early development. Technology to modify the genome of 
mESCs (discussed in Section: Homologous Recombination) was later devised and utilized for 
generating genetically altered mice by research from Mario Capecchi, Martin Evans, and Oliver 
Smithies (Doetschman et al., 1987; Kuehn et al., 1987; Thomas and Capecchi, 1987), 
revolutionizing scientific approaches for understanding biological function. 
 Most existing hESCs for experimentation, including the widely used H1 and H9 lines 
(Thomson et al., 1998), were derived from donated in vitro fertilized (IVF) embryos. The idea of 
“therapeutic cloning” as a strategy for cell therapy involved the generation of “designer” ESCs 
through somatic cell nuclear transfer (SCNT). SCNT, initially described by John Gurdon in 
tadpoles in 1962, involves the removal of the nucleus from an oocyte and its replacement with a 
donor nucleus derived from a somatic cell; therefore the genetic material (except the 
mitochondrial DNA) of the resulting oocyte comes entirely from the donor nucleus (Gurdon, 
1962). Gurdon later shared the Nobel Prize in Physiology or Medicine with Yamanaka in 2012, 
for the discovery that mature cells can be reprogrammed into pluripotent cells. Unlike 
reproductive cloning, in which the nuclear transfer oocyte develops into a new organism (e.g., 
Gurdon’s original experiments (Gurdon, 1962) and the infamous “Dolly” the sheep (Campbell et 
al., 1996)), the goal of therapeutic cloning is to derive ESCs from the nuclear transfer embryo, 
which may be used as therapeutic cell replacement to treat disease. Indeed, a hallmark paper in 
2002 demonstrated the utility of combining therapeutic cloning and gene editing for the treatment 
of genetic disorders in mice (Rideout III et al., 2002). Several years later, therapeutic cloning was 
also accomplished with human cells (Tachibana et al., 2013; Yamada et al., 2014). Patient-
specific ESCs derived from SCNT contain the patient’s nuclear DNA and would, therefore, 
reduce the risk of rejection upon transplantation. 





regulatory, and societal issues involving human cloning (Wert and Mummery, 2003). Whereas 
there are guidelines and restrictions for the uses of existing hESCs allowed in federally funded 
biomedical research, what purposes they may be used has come into question with varying 
degrees of acceptance world-wide and continuing changes in national policies. The advent of 
iPSCs, as discussed below, has largely ameliorated but not totally resolved these issues. 
 
Induced Pluripotent Stem Cells (iPSCs) 
 
Discovery 
As discussed above, the ethical and regulatory issues accompanying hESC research have 
curtailed progress especially for investigations into cell replacement therapy for degenerative 
diseases and spinal cord injury in humans. The exciting discovery in 2006 of the relatively simple 
method to reprogram somatic cells into pluripotent cells has circumvented the need for human 
embryos. In their pioneering work, Takahashi and Yamanaka selected 24 candidate genes for 
their high expression in pluripotent cells (Takahashi and Yamanaka, 2006). They used retrovirus 
to ectopically express these factors in mouse embryonic fibroblasts (MEFs) beginning with each 
factor individually and all 24 factors combined. Individual expression did not result in colonies 
with an ESC-like morphology. Conversely, expression of all 24 factors did result in ESC-like 
morphology. Factors were subsequently removed to narrow the pool with the final determination 
being octamer-binding protein 4 (OCT4), kruppel-like factor 4 (KLF4), SRY (sex-determining 
region Y)-box 2 (SOX2), and V-Myc Avian Myelocytomatosis Viral Oncogene Homolog (c-
MYC) (also called OKSM or the “Yamanaka factors”) as sufficient to induce pluripotent cells 
from MEFs and adult mouse tail-tip fibroblasts. A myriad of assays were used to determine the 
similarity of these newly termed iPSCs with ESCs including examination of gene expression with 
RT-PCR and microarrray, alkaline phosphatase staining, immunostaining with SSEA-1, in vivo 
teratoma formation, and in vitro embryoid body differentiation. One year following their initial 





reprogram human dermal fibroblasts into iPSCs (Takahashi et al., 2007). Because this technology 
has been reproducible and widely adopted by laboratories worldwide, the Nobel Prize for 
Physiology and Medicine was awarded within 6 years in 2012 to Shinya Yamanaka and shared 
with John Gurdon for their groundbreaking discoveries. 
 
Improving the protocol 
 
 In the original work the “Yamanaka factors” resulted in 0.02% efficiency for 
reprogramming MEFs (Takahashi and Yamanaka, 2006); though excitingly successful, there was 
room for improvement in efficiency. Additionally, retrovirus used in the pioneering work only 
infects dividing cells and results with the integration of the factors into the genome, a less than 
desirable outcome especially for clinical use. Subsequent work aimed to improve efficiency and 
employ footprint-free methods for iPSC generation (Malik and Rao, 2013). In the same year 
Yamanaka’s group showed OKSM were sufficient for reprogramming human somatic cells 
(Takahashi et al., 2007), a second group used lentivirus to deliver OCT4, SOX2, NANOG, and 
LIN28 for successful reprogramming of human fibroblasts (Yu et al., 2007). Equal stoichiometry 
of the reprogramming factors was shown to be crucial for successful reprogramming (Papapetrou 
et al., 2009) and to this end, polycistronic delivery systems were designed with self-cleaving 
sequences between the factors (Carey et al., 2009; Chang et al., 2009; Sommer et al., 2009), some 
of which were Cre-excisable (Chang et al., 2009; Soldner et al., 2009; Somers et al., 2010; 
Sommer et al., 2009). Nonintegrating Sendai virus has also been used for reprogramming (Ban et 
al., 2011; Fusaki et al., 2009; Seki et al., 2010) with ready-made viruses now commercially 
available. Additional methods employed include protein (Kim et al., 2009; Zhou et al., 2009), 
mRNA (Warren et al., 2010), and microRNA (Miyoshi et al., 2011; Subramanyam et al., 2011) 
transfection as well as integration followed by excision of the reprogramming factors through 
incorporation into transposable elements (PiggyBac) (Kaji et al., 2009; Woltjen et al., 2009) and 





2011; Yu et al., 2009).  
A myriad of donor cell types have been used for reprogramming since the initial 
experiments were performed in fibroblasts, including more recently cells derived from 
noninvasive urine collection (Zhou et al., 2012). Streamlined protocols now exist for the 
derivation, maintenance, and differentiation of iPSCs allowing the technology to be used by labs 
with no prior experience in stem cell research, thus expanding the impact and broad application of 
the technology. A wide variety of cell types can be generated from iPSCs including 
cardiomyocytes (Burridge et al., 2015; Lian et al., 2013; Zhang et al., 2012), skeletal myotubes 
(Darabi et al., 2012; Hosoyama et al., 2014), neural cells (Chambers et al., 2009), kidney 
podocytes (Song et al., 2012), pancreatic cells (Zhang et al., 2009), hepatocytes (Mallanna and 




 Isolation of patient-specific iPSCs made permissible the “disease in a dish” modeling of 
genetic diseases. It has nearly replaced the systems of overexpression in cancer cells and 
complements studies using animal models, which do not always faithfully recapitulate human 
disease (Avior et al., 2016). With disease in a dish modeling comes mechanistic insights into 
disease pathogenesis as well as the ability to test drugs to treat the disease in a patient’s own cells. 
Potentially the most appealing yet far reaching goal of iPSCs is either cell therapy or regenerative 
medicine. Though many obstacles exist that must be overcome before this platform develops into 
a standard practice (see Section: Limitation and caveats), some promising success has been 
demonstrated with transplantation of human iPSC-derived cells into animal models (Lamba et al., 
2010; Lian et al., 2010; Morizane et al., 2013; Rufaihah et al., 2011; Tedesco et al., 2012). 
 
Limitations and caveats 
 
 As with all model systems, it is critical to understand the limitations and caveats of 





iPSC technology is the relative immaturity of differentiated cells, more closely resembling 
embryonic as opposed to adult cell types (Bedada et al., 2016; Hrvatin et al., 2014; Spence et al., 
2011). Organoids containing multiple different cell types are becoming increasingly popular in 
studies to enhance maturation, examine paracrine factors functioning in tissues, and as 
developmental models (Lancaster and Knoblich, 2014). Another important caveat with iPSCs is 
the variability between iPSC lines with regards to differentiation efficiency resulting from both 
genetic background and the reprogramming process. Thus modest phenotypic variability is more 
difficult to discern than a robust phenotype with this model system (Soldner and Jaenisch, 2012). 
Generation of isogenic cell lines through genome editing (see Section: Genome Editing) that 
differ only at a mutation of interest aids in circumventing this limitation (Hockemeyer and 
Jaenisch, 2016). 
 The use of pluripotent stem cells (PSCs, either ESCs or iPSCs) for cell replacement 
therapies faces its own set of hurdles that must be overcome before this becomes a common 
reality (Wu and Hochedlinger, 2011). The propensity of PSCs to form tumors containing cells of 
all three germ layers (i.e., teratoma) precludes the direct injection of undifferentiated cells into 
patients. Therefore, appropriately differentiated cells to the cell type of interest must be purified 
prior to replacement in patients to ensure removal of all PSCs. Cell delivery method and 
engraftment also remains a major hurdle and will no doubt vary depending on the tissue being 
targeted. Tissue rejection, depending on whether the source is allogenic or autologous, must also 
be taken into consideration. Because some research suggests that even autologous transplant of 
certain cell types may be immunogenic (Zhao et al., 2011), this active area warrants further 
investigation. 
 Altogether, the unique qualities of iPSCs as discussed here make them increasingly 
promising for studying disease models and potential treatment of multiple diseases. Coupling 
iPSCs with recent advances in genome editing as discussed below (see Section Genome Editing) 






 As discussed in Section: Induced Pluripotent Stem Cells (iPSCs), line to line variability 
in iPSCs makes it difficult to compare among lines that have different genetic background and 
reprogramming history. The generation of isogenic iPSC lines aids in addressing these issues 
while providing investigators with the appropriate control cell lines for phenotypic analysis. 
Additionally, a requirement exists for genome editing in order to correct a disease allele ex vivo 
within a patient’s own cells for cell replacement therapy. Alternatively, genome editing may be 
performed in vivo for genetic correction of disease alleles. Though useful in mESCs (Doetschman 
et al., 1987; Thomas and Capecchi, 1987), homologous recombination alone as a method for 
genome editing is highly inefficient and impractical in hiPSCs (see Section: Homologous 
recombination). The advent of site-specific nucleases (SSNs) in recent years has greatly enhanced 
the efficiency of genome editing in PSCs and will be discussed in this section.  
 
Homologous recombination 
 Homologous recombination refers to the genetic base pairing that occurs when nucleotide 
sequences are exchanged between two homologous (similar or identical) regions of DNA. 
Conventional genome modification through homologous recombination, discovered by work 
from 2007 Nobel Prize winners Mario Capecchi, Oliver Smithies, and Martin Evans (Doetschman 
et al., 1987; Kuehn et al., 1987; Thomas and Capecchi, 1987) provided a means to generate 
specific gene modifications in mESCs. However, hPSCs are more refractory to this type of 
modification, likely due to lower rates of endogenous homologous recombination. Though some 
success of modifying the genome in this way has been presented in hPSCs (An et al., 2012; Costa 
et al., 2007; Davis et al., 2008; Howden et al., 2011; Irion et al., 2007; Ruby and Zheng, 2009; 
Urbach et al., 2004; Zwaka and Thomson, 2003), it remains a highly inefficient and time 
consuming process. SSNs (described in Sections: ZFNs and TALENS and CRISPR/Cas9), 





and more recently, the clustered regularly interspaced short palindromic repeats 
(CRISPR)/CRISPR-associated 9 (Cas9) (CRISPR/Cas9) system have enhanced the efficiency of 
homologous recombination making specified genetic modification in human cells more feasible.  
 
ZFNs and TALENs 
SSNs are designed to generate targeted double strand breaks (DSBs) in the genome, 
which require repair for cell survival and proliferation (Figure 2.2). The repair pathways for 
DSBs include homology-directed repair (HDR), repair that occurs through homologous 
recombination (Jasin and Rothstein, 2013), and nonhomologous end joining (NHEJ), a DSB 
repair that results in direct ligation of the cut ends of DNA and can generate insertion or deletion 
mutations in the process (Lees-Miller and Meek, 2003) (Figure 2.2). The observation that a DSB 
in the genome enhances the efficiency of HDR was first made in mammalian cells during 
experiments utilizing the restriction enzyme I-Sce I to examine the modes of repair (Rouet et al., 
1994a, b). This initial observation formed the basis for which SSNs where investigated as a tool 
for genome editing. 
Zinc finger nucleases (ZFNs), which are a coupling of zinc finger proteins with a 
restriction enzyme, such as FokI, specifically cut DNA at the zinc finger protein recognizing 
sequence (Kim et al., 1996; Smith et al., 1999). For FokI cleavage of DNA, it must form a dimer; 
therefore, two adjacent ZFNs are designed in specific orientations, each coupled with a single 
FokI, to accomplish this feat, providing increased specificity (Smith et al., 1999). Zinc finger 
domains recognize nucleotides in triplets and have been designed to recognize nearly all possible 
nucleotide triplet combinations (Gaj et al., 2013). ZFNs were first shown to enhance gene 
targeting in 2003 (Bibikova et al., 2003) and utilized in 2005 to modify the endogenous human 
genome and the term “genome editing” was coined (Urnov et al., 2005). 
TALENs are transcription activator-like effector (TALE) proteins fused to a nuclease, 






TALEs were discovered as naturally occurring proteins in plant pathogenic bacteria (Gu et al., 
2005; Kay et al., 2007; Sugio et al., 2007; Yang et al., 2006) and shown to have a simple 
recognition pattern of a pair of amino acid residues recognizing one nucleotide (Boch et al., 2009; 
Moscou and Bogdanove, 2009), making them simpler to design compared with ZFNs, though 
initially more difficult to generate due to the presence of repeat sequences (Gaj et al., 2013).  
Despite the time intensive and costly nature of generating and/or purchasing custom 
ZFNs and TALENs, many studies have utilized them for genome editing in hPSCs generating 
gene knockouts, insertion or repair of point mutations, insertion of transgenes, and generation of 
reporters (DeKelver et al., 2010; Hockemeyer et al., 2009; Lombardo et al., 2007; Mitzelfelt et 
al., 2016; Soldner et al., 2011; Yusa et al., 2011). The simpler, cheaper, next generation version 
of SSNs came in the form of CRISPR/Cas9 (see Section: CRISPR/Cas9). 
 
Figure 2.2 Schematic representation of genome editing. Site specific nucleases (SSNs) are 
designed to generate targeted double strand breaks (DSBs) within the genome and include 
zinc finger nucleases (ZFNs), transcription activator-like effector nucleases (TALENs), and 
the clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR-associated 9 
(Cas9) (CRISPR/Cas9) system. DSBs are repaired either through nonhomologous end joining 
(NHEJ) or homology-directed repair (HDR). The former generates insertion/deletion 
mutations (indels)- potentially gene knockouts- and the latter allows targeted knock-in of 






As described in Section: ZFN and TALEN, both ZFNs and TALENs interact with DNA 
through a protein/DNA interaction, making them more difficult to design and construct. The 
recently adapted use of the CRISPR/Cas9 system as an engineered SSN provided an answer to 
these issues as it works through an RNA/DNA interaction- Watson and Crick base pairing- 
making design and construction simple.  
The CRISPR/Cas system is a naturally occurring adaptive immunity response in bacteria 
and archaea where viral infection results in the insertion of a small sequence of the viral genome 
into the CRISPR locus of the bacterium (or archaeum) that is then transcribed into RNA to bind 
and direct the cleavage of the viral genome by Cas proteins (Marraffini, 2015). Much research 
has gone in to understanding the bacterial system (Hsu et al., 2014) stemming from the initial 
finding of a set of a novel type of repeat interspaced by nonrepetitive sequences in the 
Escherichia coli genome in 1987 (Ishino et al., 1987). Similar sequences were later shown to be 
present in 90% of archaea and >40% of bacteria (Mojica et al., 2000), with the term CRISPR 
being coined in 2002 along with the identification of associated Cas genes (Jansen et al., 2002). 
Three types of CRISPR systems exist (Type I-III) based on the associated Cas genes (Haft et al., 
2005; Makarova et al., 2011) with Type II being the system adopted for genome editing utilizing 
Cas9. 
Though CRISPRs were known to be transcribed in bacteria/archaea (Tang et al., 2002), 
their exogenous, viral origin was not appreciated until 2005 (Bolotin et al., 2005; Mojica et al., 
2005; Pourcel et al., 2005). The role of CRISPRs as an adaptive immune response was predicted 
from this finding, and the first experimental evidence showing that CRISPRs direct Cas9 
cleavage of viral DNA came in 2007 (Barrangou et al., 2007).  
In the native Type II CRISPR/Cas9 system, the genomic CRISPR array is transcribed as 
a single RNA and then cleaved to form short CRISPR RNAs (crRNAs), providing specificity for 





required for cleavage of the CRISPR array. These two components (crRNA and tracrRNA) 
together with the target DNA provide a scaffold for Cas9 to fold and bind for DNA cleavage (Hsu 
et al., 2014). A crRNA and a tracrRNA can be fused into a single guide RNA (sgRNA) for 
efficient engineered cleavage suggesting its use as a SSN similar to ZFNs and TALENs in 
genome editing (Jinek et al., 2012). The protospacer-adjacent motif (PAM) within the target DNA 
is essential for Cas9 nuclease activity. The specific sequence and location vary between species 
and Cas proteins (Hsu et al., 2014). Overall the components for DSB generation by the 
CRISPR/Cas9 system include: crRNA/tracrRNA complex (or sgRNA), Cas9 protein, and target 
DNA containing a PAM site.  
Adapting the CRISPR/Cas9 bacterial system to applications in genome editing is 
relatively simple. One must design a guide sequence (originally 20 nucleotides, with many online 
tools available for assistance http://zifit.partners.org/ZiFiT/ and http://www.rgenome.net/) and 
incorporate this into a sgRNA coexpressed with Cas9. Design limitation stems from the 
requirement for a PAM site in the appropriate orientation to the target site (Hsu et al., 2014). 
Design and construction are much simpler compared with their predecessors ZFNs and TALENs. 
The first demonstration of genome editing utilizing CRISPR/Cas9 in eukaryotic cells occurred in 
2013 (Cong et al., 2013; Mali et al., 2013b), with exponential expansion of the use of the 
technology since then, including in hPSCs (Hinson et al., 2015; Smith et al., 2014; Wang et al., 
2014; Xie et al., 2014). Multiple published protocols exist for genome editing in hPSCs (Blair et 
al., 2016; Byrne and Church, 2015; Chiba and Hockemeyer, 2015; Yusa, 2013). 
 
Improving genome editing 
 As with any new application, modifications to genome editing protocols optimize the 
impact. The CRISPR/Cas9 system continues to be widely studied with the hopes of further 
improving efficiency, enhancing specificity, and broadening flexibility. 





homologous recombination alone, there still exists room for improvement. An elegant strategy 
aimed to alleviate this issue incorporates positive selection for the editing event. Kosuke Yusa, 
developed and utilized this strategy for the correction of a mutation causing α-1 antitrypsin 
deficiency (Yusa et al., 2011). Targeting was performed at the region of interest to knock-in a 
selection cassette flanked by PiggyBac repeats followed by subsequent excision of the selection 
cassette through transfection with PiggyBac transposase resulting in seamless or ‘scar-free’ 
editing of the locus of interest (Yusa, 2013; Yusa et al., 2011). A similar approach utilizing the 
Cre-LoxP system was utilized to correct point mutations in the beta-globin gene leaving a single 
LoxP site within an intronic region (Zou et al., 2011). A downfall to these approaches is the 
requirement for two separate targeting steps, the first to incorporate the selection cassette and the 
second to remove it. A separate strategy develop by Bruce Conklin’s group involves serial 
enrichment of positive subfractions (sib-selection) that allows for more efficient isolation of rare 
editing events (Miyaoka et al., 2014).  
 Cell cycle synchronization and transfection of preassembled Cas9-guide RNA 
ribonucleoprotein (RNP) has been shown to enhance HDR efficiency preferentially over NHEJ 
depending on cell cycle timing of RNP application (Lin et al., 2014). This is important as NHEJ 
remains the dominant repair pathway for DSBs (Chapman et al., 2012). Additional work has 
utilized chemical inhibitors, such as Scr7, to block NHEJ resulting in higher rates of HDR 
(Maruyama et al., 2015). hPSC lines with knock-in of doxycycline-inducible Cas9 into the 
AAVS1 safe-harbor locus have been generated thereby requiring only transfection of an sgRNA 
for targeting simplifying the process (González et al., 2014). Genome editing has also been 
combined with iPSC reprogramming in a simultaneous process beginning with patient fibroblasts 
thereby creating a streamlined approach for regenerative therapy (Howden et al., 2015). 
 Despite these improvements in this exciting, rapidly progressing field, it has not yet 
reached an optimal point in which efficient editing can be performed at virtually any locus 





isolation of cells bearing a selectable, HDR-mediated editing event at one locus enriches many-
fold for the introduction of additional HDR-mediated edits at secondary, investigator-specified 
loci (see Chapter 4) is aimed towards this goal.  
 Specificity and off-target cleavage are concerns for all SSNs, especially CRISPR/Cas9, 
which is thought to be more promiscuous compared with ZFNs and TALENS due to their 
cooperative nature. Enhancing the specificity of Cas9 and identifying unbiased methods to screen 
for off-target effects are high priorities. Mismatches occurring throughout the guide sequence 
impact Cas9’s ability to cleave DNA and interestingly, though guides with lower levels of 
homology result in binding, cleavage efficacy is negatively impacted through mismatches (Wu et 
al., 2014). Higher concentrations of Cas9 correlate with elevated off-target effects (Hsu et al., 
2013; Pattanayak et al., 2013) suggesting that using lower levels of Cas9 should enhance 
specificity, though the efficiency of on-target cleavage is also reduced (Hsu et al., 2013).  
 Modification of Cas9 to generate single strand breaks or nicks in the DNA opposed to 
DSBs has allowed a dimeric approach similar to ZFNs and TALENs, which requires pairs of 
guide RNAs specifically placed to generate DSBs and therefore increases the number of matching 
bases required for cleavage (Mali et al., 2013a; Ran et al., 2013). Single DNA nicks cannot be 
repaired by NHEJ, but can be repaired by HDR, though the efficiency is lower compared with 
DSBs (Hsu et al., 2013). Shorter guide RNAs (17-19 bp as opposed to 20 bp) have been shown to 
decrease off-target effects without the loss of on-target efficiency (Fu et al., 2014). A high fidelity 
version of endogenous Cas9 has been generated that contains sequence alterations designed to 
reduce nonspecific DNA contacts while retaining on-target activity (Kleinstiver et al., 2016). 
Though significant off-target effects have been observed in cancer cells, it is generally thought 
that primary cells, such as hPSCs with intact cell cycle checkpoints, undergo lower levels of off-
target nuclease cutting though this has not been fully addressed (Hockemeyer and Jaenisch, 
2016). 





becomes increasingly important as we envisage their clinical use. Initially, off-target sites were 
computationally identified looking for similarity in genomic sequences using available online 
tools (e.g., http://zifit.partners.org/ZiFiT/ or http://www.rgenome.net/) followed by subsequent 
screening for off-target cutting with direct sequencing. Recent studies have shown that 
computationally identified off-target sites do not always account for actual off-target sites (Tsai et 
al., 2015). Keith Joung’s group has developed a rigorous strategy for unbiased off-target site 
identification, termed GUIDE-Seq, which involves the incorporation of a double-stranded piece 
of exogenous DNA into a DSB (Tsai et al., 2015). Though strategies such as GUIDE-Seq should 
be used as a preclinical screening mechanism, for most basic research purposes appropriate 
experimental controls should account for differences generated due to off-target effects.  
 Improving the flexibility of the CRISPR/Cas system is another pursued endeavor. Much 
of the initial work was performed with the CRISRP/Cas9 system adopted from Streptococcus 
pyogenes (Cong et al., 2013; Jinek et al., 2012; Mali et al., 2013b), with limited work also 
performed using the Streptococcus thermophilus LMD-9 CRISPR1 system (Cong et al., 2013), 
termed SpCas9 and StCas9, respectively. SpCas9 utilizes a 5’-NGG-3’ PAM sequence, while 
StCas9 recognizes a 5’-NNAGAAW-3’ (W= A or T) PAM sequence, limiting target design to 
locations in the genome adjacent to those sequences. Additional work with other species of Cas9 
including Neisseria meningitidis (NmCas9) provides further options for PAM sequences (Hou et 
al., 2013). Additionally, the use of Cpf1 in place of Cas9 offers variability as well since it 
recognizes a T-rich PAM upstream of the target site, does not require a tracrRNA, and introduces 
a staggered DSBs as opposed to the blunt DSBs introduced by Cas9 (Zetsche et al., 2015). 
Additional work has been performed by Keith Joung’s group to modify SpCas9 and Cas9 derived 
from Staphylococcus aureus (SaCas9) altering their PAM recognition sequences generating 








Summary and perspectives 
 The rapid-paced genome engineering field continues to grow and expand with more labs 
feasibly utilizing the now simplified techniques. The first clinical trials involving transplantation 
studies using ZFNs to disrupt the CCR5 locus in autologous patient CD4 T cells were performed 
with relative success in a small cohort (Tebas  et al., 2014). Many companies are currently 
investigating therapeutic treatments utilizing genome editing with SSNs with many likely 
therapeutic prospects such as transplantation of autologous T cells genetically modified at the 
CCR5 locus for treatment of human immunodeficiency virus (HIV) and treatment of Duchenne’s 
muscular dystrophy through either in vivo or ex vivo restoration of the dystrophin reading frame 
by exon deletion (Maeder and Gersbach, 2016; Sheridan, 2015).  
Though most agree therapeutic modifications of the genome warrant investigation, 
engineering the human germline is not met with such enthusiasm and much skepticism exists in 
terms of societal benefits. The ease of CRISPR/Cas9 genome editing sparked this ethical debate, 
as now any molecular biology-equipped laboratory can perform editing experiments, and will 
require policy regulation (Hockemeyer and Jaenisch, 2016). Policy will likely vary worldwide, as 
already two separate groups in China have performed editing in nonviable human embryos (Kang 
et al., 2016; Liang et al., 2015). A distinction must be made between modification for therapeutic 
purposes and germline modification, which results in permanent, transmissible modification of 
the human genome (Hockemeyer and Jaenisch, 2016). 
 
The Combined Power of iPSCs and Genome Editing 
 
 Ten years of exciting recent work with the advent of iPSCs and the CRISPR/Cas9 system 
for genome engineering have opened the door for regenerative therapies involving cell and gene 
replacement. This work is based on the foundational discoveries of ESCs and homologous 
recombination/ZFNs, studied since the 1980s. Though many challenges to bring these grand ideas 





lead towards standard clinical treatments. Chapter 3 of this work provides an example 
incorporating the use of iPSC and genome editing technologies in the study of 343delT HSPB5 
associated with early-onset skeletal myopathy, introduced in Chapter 1. Chapter 4 presents a 
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Genome editing in induced pluripotent stem cells is currently hampered by the laborious 
and expensive nature of identifying homology-directed repair- (HDR) modified cells. We present 
an approach where isolation of cells bearing a selectable, HDR-mediated editing event at one 
locus enriches for HDR-mediated edits at additional loci. This strategy, called cotargeting with 
selection, improves the probability of isolating cells bearing HDR-mediated variants and 
accelerates the production of disease models. 
 
Introduction 
Programmable nucleases are seeing widespread application in the genome engineering 
field on account of their ability to permit precise genetic modifications in cell cultures and whole 
organisms. The CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats)/Cas9 
(CRISPR-associated) system (Bhaya et al., 2011) has attracted particular attention on account of 
its flexibility, ease of use, and cost-effectiveness compared to alternative nucleases (e.g., Zinc 
finger nucleases (ZFNs) and Transcription activator-like effector nucleases (TALENs)). 
Approaches utilizing ZFNs, TALENs, and increasingly CRISPR/Cas9 for the creation of 
genetically-modified induced pluripotent stem cell (iPSC) lines which can be converted into 
pertinent somatic cell-types for exploration of contextually-relevant pathophysiological states 
have become a go-to strategy for delineating variant/disease association, reviewed in Hockemeyer 
and Jaenisch 2016 (Hockemeyer and Jaenisch, 2016). Precision genome editing typically involves 
incorporation of an exogenously-supplied DNA donor with the desired variant –often containing 
one or more additional sequence incorporations to prevent nuclease re-cutting (Long et al., 2014)- 
into the host cell’s genome via the homology-directed repair (HDR) pathway following a 
nuclease-mediated double-strand break. Despite enhancements in the efficiency with which donor 
DNA can be incorporated into the genome, HDR-based editing in iPSCs using either vector- or 





1% (Soldner et al., 2011; Wang et al., 2014). Consequently, identifying a cell that bears a 
mutation of interest – which can entail extended maintenance, expansion, and analysis of 
hundreds of clonal populations - is laborious, expensive and not readily scalable.  
Increasing evidence suggests HDR, which represents the lesser-used method of genome 
repair, is dependent on various cell-autonomous factors. Mitotic manipulation, temporal 
regulation of Cas9 expression, and suppression of the nonhomologous end joining (NHEJ) 
pathway have all been shown to enhance HDR editing in vitro to varying degrees (Gutschner et 
al., 2016; Lin et al., 2014; Maruyama et al., 2015; Yu et al., 2015). Elegant strategies have also 
been devised to enhance isolation of precision-modified clones, including precision knock-in of 
excisable selectable cassettes and serial enrichment of positive subfractions (Miyaoka et al., 2014; 
Yusa et al., 2011). Here we implemented a simple and adaptable method that obviates chemical 
perturbation, avoids stable Cas9 expression, maintains inherent DNA repair competence, does not 
require additional time or equipment, and is applicable to mismatch repair-proficient cell systems. 
We envisaged a potential HDR-competence spectrum across any population of transfected iPSCs, 
whereby a small subpopulation would naturally be more receptive to the incorporation of donor 
DNA via HDR while other cells remain refractory. In such a receptive cell, multiple independent 
HDR events could occur simultaneously meaning in theory an HDR-based primary editing event 
to incorporate a selectable marker at one locus could be accompanied by one or more 
independent, specified, HDR-mediated edits. Hence, isolation of cells based on the primary, 
selectable modification would enrich for the secondary, passenger modification(s).  
To test our hypothesis, we devised and implemented a strategy that we refer to as 
cotargeting with selection (CTS). CTS involves simultaneous transfection of human iPSCs with 
(i) a nuclease and donor plasmid designed to incorporate, via HDR, an antibiotic-resistance 
cassette into the AAVS1 safe-harbor site (Sadelain et al., 2012) on chromosome 19, and (ii) 
CRISPR/Cas9-based reagents and a cognate ssODN designed to introduce a variant of interest at 





days to select for resistant (and theoretically HDR-competent) clones (Figure 4.1a-b). Antibiotic-
resistant colonies are then isolated, clonally expanded and screened for knock-in of the variant of 
interest. CTS does not alter the duration from transfection to isolation and analysis, but based on 
our experience and data reported herein, markedly enhances the representation of cells bearing 
knock-in alleles in the final population. 
 
Results and Discussion 
We first applied the CTS method to a single gene (CRYAB) in hB53 hiPS6 iPSCs (Riedel 
et al., 2014). Following transfection of a prevalidated CRYAB-specific single guide RNA 
(sgRNA)-expressing pX330 vector and ssODN donor template as well as a commercially-
available AAVS1-specific TALEN pair and puromycin N-acetyl-transferase (pac)-containing 
donor vector driven by a constitutive promoter, cells were treated with puromycin per our CTS 
protocol (to enrich for cells that underwent HDR, Figure 4.2), for 48 h (to eliminate untransfected 
cells) or not at all (to mimic a selection-free system) (Figure 4.3). Clones were then harvested and 
analyzed via Sanger sequencing. The total number of editing events (NHEJ and HDR) was >7-
fold greater in CTS cells relative to unselected cells and, crucially, the HDR/NHEJ ratio was >4-
fold greater (Figure 4.1c, left panel and Table 4.1). This corresponded to a ~40% likelihood of 
picking a precision-modified clone, both heterozygous and homozygous, from the final culture 
with CTS compared to 2% (no treatment) or 4% (transient puromycin treatment) (Figure 4.1c, 
middle and right panel and 4.1d). Contrary to previous findings in which merely selecting cells 
based on reagent delivery increased HDR (Ding et al., 2013), we did not observe enhancement in 
donor incorporation following isolation of transiently-transfected cells. In sum, this data 
suggested that selecting for HDR-receptive cells via a selectable modification significantly 
enriched for cells bearing precision edit events at the site of interest. 
To benchmark the impact of CTS on HDR representation in a more quantitative manner 









Figure 4.1: Rationale for cotargeting with selection (CTS) and proof of feasibility. (a) 
Cells are edited simultaneously with gene-specific CRISPR/Cas9 and ssODN containing a 
variant of interest (blue asterisk) as well as plasmids expressing AAVS1-specific TALENs 
and a puromycin resistant (Puro
R
) donor cassette. (b) Components from (a) are transfected 
into iPSCs where HDR-receptive cells (green) are more likely to incorporate donor DNA 
than HDR-refractory cells (red). (c) Precision-edited versus indel-containing alleles, detected 
via Sanger-sequencing in hB53 hiPS6 iPSCs following CTS (n=39) compared to no 
selection (n=46) or transient exposure to puromycin (n=48) (left panel). Percent of clones 
bearing the CRYAB:c.325G>C variant (middle panel) and the number of 
heterozygous/homozygous clones (right panel). (d) Representative chromatograms showing 
local CRYAB sequence of a wild-type (WT) clone (top) and that of a clone bearing a 
CRYAB:c.325G>C (homozygous) knock-in allele (black arrow, c.325G>C variant; grey 











Figure 4.2: Timeline for CTS protocol. iPSCs are transfected with targeting components 
shown in Figure 4.1a on day 0 (D0) and plated at high density on matrigel to promote survival 
in mTeSR1 medium supplemented with ROCK inhibitor. On D1, media is changed to fresh 
mTeSR1 and dead cells are washed away. Cells are passaged on D2 to mitomycin-C-treated 
SNL feeders cells at low density. Puromycin selection (0.5 μg/ml) is performed D5-picking 
time (~D12-16) in order to limit selection based on transient expression of puromycin 
resistance and promote selection for incorporation of the puromycin cassette into the AAVS1 
locus. Selection is continued until picking to ensure all cells picked are puromycin resistant. 
Colonies are manually picked ~D12-16, with half of the colony utilized for genotyping while 












Figure 4.3: Experimental design comparing selection methods. Experimental design 
employed for comparing selection strategies (no selection, transient selection, and CTS) used 












Table 4.1: Genotypes of clones analyzed comparing different selection strategies.  
 
Selection None Transient CTS 
WT/WT 39 43 4 
WT/Indel 3 1 4 
Indel/Indel 1 1 6 
Knock-in/Indel 1 2 3 
Blocking/Indel 0 0 1 
WT/Knock-in 0 0 2 
Knock-in/Knock-in# 0 1 9 
WT/Blocking 1 0 1 
Blocking/Blocking# 0 0 2 
Knock-in/Blocking 1 0 7 
Total 46 48 39 
 
Genotypes of clones analyzed and presented in Figure 4.1c. “Blocking” indicates knock-in of 
only the silent, Cas9-blocking mutation (i.e., without the variant of interest), whereas “Knock-in” 
indicates incorporation of both the silent mutation and variant of interest. ‘WT’ indicates 
unmodified alleles. CTS column from this table is the same data shown in Table 4.3.  
#
Though these clones appear to be homozygous through Sanger sequencing (i.e., “clean” 
sequence), a Southern blot would be required prior to phenotyping to ensure there is not a large 






across four different genes (CRYAB, BAG3, LMNA, and MTERF4) in two separate iPSC lines 
(hB53 hiPS6 and hB119 hiPS9) and analyzed editing outcomes via deep-sequencing. Following 
CTS, cells were pooled and deep-sequenced using the Illumina MiSeq platform. Average 
sequencing coverage following read trimming and quality filtering across all experiments was 
>150,000x and error rate was estimated to be less than 0.1%. We observed an average 3.7-fold 
(hB53 hiPS6) and 3.3-fold (hB119 hiPS9) increase in the total number of edits (HDR and NHEJ) 
across all loci with CTS compared to without (Table 4.2). Focusing on precision editing events 
and considering all seven variants, we observed an average 50-fold increase in HDR with CTS 
compared to without in both cell lines (Figure 4.4a-c and Table 4.2). In support of our hypothesis 
that CTS enriches for HDR, we observed an overt shift in the balance between the two modes of 
repair such that the HDR/NHEJ ratio was enhanced on average 18-fold (hB53 hiPS6) and 27-fold 
(hB119 hiPS9) with CTS compared to without (Figure 4.4d-f and Table 4.2). Considering all loci 
and both cell lines, the HDR rate following CTS was ~14%, which corresponds to >1 in 10 clones 
bearing a precision edit.  
While CTS led to a gross increase in precision editing, deep-sequencing data revealed 
significant variation in locus targetability. For example, representation of the CRYAB:c.343delT 
variant was 22% (hB53 hiPS6) and 25% (hB119 hiPS9) following CTS (1% (hB53 hiPS6) and 
3% (hB119 hiPS9) without CTS), whereas representation of the LMNA:c.1346G>T variant was 
1% (hB53 hiPS6) and 4% (hB119 hiPS9) HDR following CTS (<0.05% in both cell lines without 
CTS). Notwithstanding, the average >100-fold increase in HDR at LMNA with CTS means 
isolating a precision-edited clone is feasible (~1 cell in 40 with CTS compared to ~1 cell in 
~3,800 without, assuming heterozygosity) and suggests that loci which are inherently refractory 
to precision editing may be amenable via CTS.  
We next assessed how reflective the HDR editing rates calculated via deep-sequencing 











Figure 4.4: Quantitative analysis of CTS-enabled precision editing across multiple genes. 
Representation of precision (HDR only) editing events, based on read sequence and 
normalized to total read count, with (+) and without (-) CTS at multiple loci in hB53 hiPS6 (a) 
and hB119 hiPS9 (b) iPSC lines. (-) CTS indicates cells handled in the same way as (+) CTS 
except for the addition of puromycin. (c) Average fold-change in HDR-mediated knock-in 
with CTS relative to without, considering all loci in hB53 hiPS6 and hB119 hiPS9 iPSC lines. 
Relative proportions of reads bearing NHEJ- and HDR-based edits with (+) and without (-) 
CTS at multiple loci in hB53 hiPS6 (d) and hB119 hiPS9 (e) iPSC lines. (f) Average increase 






Table 4.2: Illumina MiSeq experimental results. 
 




HDR NHEJ WT 
Sample # reads % of total # reads % of total # reads % of total 
CRYAB:c.343delT_CTS- 262144 152720 2458 1 150262 57 109424 42 
CRYAB:c.343delT_CTS+ 134752 134752 30210 22 86683 64 17859 13 
CRYAB:c.325G>C_CTS- 264167 168170 2967 1 165437 63 95997 36 
CRYAB:c.325G>C_CTS+ 135680 123981 17227 13 106754 79 11699 9 
CRYAB:c.358A>G_CTS- 233189 129405 2568 1 126837 54 103784 45 
CRYAB:c.358A>G_CTS+ 299329 282460 37946 13 244515 82 16869 6 
BAG3:c.1430G>A_CTS- 155400 13104 439 0 12665 8 142296 92 
BAG3:c.1430G>A_CTS+ 183997 61279 8526 5 52753 29 122718 67 
BAG3:c.1402G>A_CTS- 180651 14651 108 0 14543 8 166000 92 
BAG3:c.1402G>A_CTS+ 160393 50311 8042 5 42269 26 110082 69 
LMNA:c.1346G>T_CTS- 207467 9211 20 0 9191 4 198256 96 
LMNA:c.1346G>T_CTS+ 202658 25455 2410 1 23045 11 177203 87 
MTERF4:c.693delATA_CTS- 188846 9255 353 0 8902 5 179591 95 
MTERF4:c.693delATA_CTS+ 174497 90735 29916 17 60819 35 83762 48 
Average_CTS- 213123 70931 1273 0.4 69691 28.4 142193 71.1 
Average_CTS+ 184472 109853 19182 10.9 88120 46.6 77170 42.7 
 




HDR NHEJ WT 
Sample # reads % of total # reads % of total # reads % of total 
CRYAB:c.343delT_CTS- 121572 23748 3108 3 20640 17 97824 80 
CRYAB:c.343delT_CTS+ 110499 108887 27905 25 80982 73 1612 1 
CRYAB:c.325G>C_CTS- 118811 69039 774 1 68265 57 49772 42 
CRYAB:c.325G>C_CTS+ 109238 75900 9260 8 66640 61 33338 31 
CRYAB:c.358A>G_CTS- 100932 16806 2447 2 14359 14 84126 83 
CRYAB:c.358A>G_CTS+ 77869 75359 41505 53 33854 43 2510 3 
BAG3:c.1430G>A_CTS- 91759 7878 139 <1 7739 8 83881 91 
BAG3:c.1430G>A_CTS+ 98513 21496 10510 11 10986 11 77017 78 
BAG3:c.1402G>A_CTS- 95556 6920 37 <1 6883 7 88636 93 
BAG3:c.1402G>A_CTS+ 207563 45135 11727 6 33408 16 162428 78 
LMNA:c.1346G>T_CTS- 112816 5463 48 0 5415 5 107623 95 
LMNA:c.1346G>T_CTS+ 220533 42597 8521 4 34436 16 177576 81 
MTERF4:c.693delATA_CTS- 130614 9997 1087 1 8910 7 120617 92 
MTERF4:c.693delATA_CTS+ 93752 11555 8111 9 3444 4 82197 88 
Average_CTS- 110294 19979 1091 1.4 18887 16.4 90354 82.3 
Average_CTS+ 131138 54418 16791 16.6 37679 32.0 76668 51.4 
 
MiSeq experimental results for each cell line (hB53 hiPS6- top and hB119 hiPS9- bottom) 
including total number of reads, total number of edits, number of reads with HDR, percent of 
reads with HDR, number of reads with NHEJ, percent of reads with NHEJ, number of WT 
(unmodified) reads, and percent WT reads. Data for each variant with (CTS+) and without (CTS-








independently and approximately 250 clonal populations were then picked and analyzed via 
Sanger sequencing. We successfully isolated cell lines for all seven mutations and observed a 
concordance between the quantities of HDR editing events determined via deep-sequencing and 
direct sequencing (Figure 4.5, Figure 4.6, and Table 4.2-4.3). We note that pooled deep-
sequencing measures allelic representation at a specific time-point and does not reflect zygosity 
or account for differing cellular growth rates from which the pool was derived. Extent of 
heterozygosity seemed to correlate, at least for the CRYAB mutations, with increasing distance 
from the CRISPR/Cas9 cut-site (i.e., increased observation of heterozygous knock-in clones with 
CRYAB:c.325G>C), but not in the case of BAG3:c.1430G>A, where we failed to isolate any 
mutant homozygous lines even though the targeted nucleotide was immediately adjacent to the 
CRISPR/Cas9 cut-site. We speculate, as others have, that the nature and extent of zygosity is 
dictated by distance between the CRISPR/Cas9 cut-site and the targeted nucleotide as well as 
locus-dependent factors such as chromatin organization (Paquet et al., 2016; Ward, 2015; Yang et 
al., 2013). As expected representative cell lines harbored the pac cassette at AAVS1 (Figure 4.5) 
and none displayed evidence of additional aspecific integration events (Experimental 
Procedures). Analyzing clones picked from two knock-in experiments revealed a 10% random 
integration rate of the AAVS1 donor vector (Experimental Procedures). Additionally, all lines 
analyzed exhibited the typical pluripotent cell morphology and karyotypic stability as well as 
expression of pluripotency markers (Figure 4.5), and maintained a capacity to form high-
representation cardiomyocyte cultures (data not shown). 
Despite improvements in sgRNA design (Doench et al., 2016), we nevertheless analyzed 
the top potential off-target sites (Experimental Procedures) in multiple mutant cell lines via 
Sanger sequencing and detected no signs of aspecific cleavage (data not shown). Furthermore, 
deep-sequencing of 12 potential off-target sites (Experimental Procedures) associated with the 
most active sgRNA (CRYAB) in pooled populations of cells, with and without CTS, revealed no 











Figure 4.5: Validation of knock-in cell lines generated with CTS. Knock-in clones were 
generated for each disease-associated variant of interest shown in Table 4.3, with 
representative clones harboring variants in each gene shown here. Chromatograms (chromats) 
showing Sanger sequencing results of original cell line (WT) and knock-in line (KI) with 
variants indicated by black arrows. Immunocytochemistry showing pluripotency markers 
Nanog and SSEA-4 for each knock-in cell line harboring the respective variant of interest. 
Images were merged and counterstained with DAPI. Size bar indicates 100μm. Representative 
karyotypes for each cell line. Agarose gel showing AAVS1 inside-out PCR for both the 5’ 
(middle lane) and 3’ (right lane) integration sites (Experimental Procedures), which 












Figure 4.6: Concordance between deep-sequencing pooled samples and direct 
sequencing clonal samples. (a) Correlation of allelic HDR frequency between deep-
sequencing (MiSeq) of pooled populations and Sanger sequencing of clonal populations. (b) 
Representative examples of high (CRYAB:c.325G>C) and low (LMNA:c.1346G>T) 
efficiency loci showing genotypes derived from clonally expanded populations. “Blocking” 
indicates knock-in of only the silent, Cas9-blocking mutation (i.e., without the variant of 
interest), whereas “Knock-in” indicates incorporation of both the silent mutation and variant 
of interest. “WT” indicates unmodified alleles. Genotypes are categorized as not-targeted 























Location 11q23.1 10q25.2-q26.2 1q22 2q37.3 




































(Vicart et al., 
1998) 
(Norton et al., 
2011) 













SBI Transposagen SBI SBI Transposagen SBI 
sgRNA/ssOD
N Orientation 
R+ R+ R+ R- R- R+ R- 
Cell Line hB53 hiPS6 hB53 hiPS6 hB53 hiPS6 hB53 hiPS6 hB53 hiPS6 hB119 hiPS9 hB53 hiPS6 
Genotype 
Unmodified 9 4 13 61 75 22 13 
WT/Indel 0 4 0 2 7 3 0 
Indel/Indel 4 6 5 0 2 2 2 
Knock-in/indel 0 3 0 1 1 1 4 
Blocking/Indel 0 1 0 0 1 0 0 
WT/Knock-in 0 2 0 1 3 1 0 
Knock-
in/Knock-in# 
1 9 2 0 1 0 11 
WT/Blocking 0 1 0 0 0 0 0 
Blocking/Bloc
king# 
0 2 0 0 0 1 0 
Knock-
in/Blocking 
0 7 0 0 1 0 0 
Total 14 39 20 65 91 30 30 
 
Variants of interest knocked-in to iPSCs using CTS. Gene name, mutation, corresponding protein 
change, disease, and references are given for each variant. The AAVS1 targeting vector utilized in 
each case is shown (see Experimental Procedures). The sgRNA/ssODN orientation is listed as 
either R+ or R-, indicating agreement or disagreement with the Richardson et al. model for 
ssODN strand design (Richardson et al., 2016). The cell line utilized to generate each variant is 
also listed (hB53 hiPS6 or hB119 hiPS9). The numbers of clones isolated with each genotype are 
indicated below each variant. 
*
The patient variant MTERF4:c.[693delATA];[787C>T] was 
generated by an ssODN incorporating c.693delATA and screening for an indel on the second 
allele to mimic c.787C>T, which generates a stop codon. 
#
Though these clones appear to be 
homozygous through Sanger sequencing (i.e., “clean” sequence), a Southern blot would be 
required prior to phenotyping to ensure there is not a large deletion on one allele that prevents 





previously demonstrated to have minimal off-target cleavage (Hockemeyer et al., 2011) and 
aspecific integration profiling revealed extremely low rates of random integration of the donor 
plasmid. Collectively, these data suggest negligible reagent promiscuity and that while CTS 
specifically enriches for cells bearing HDR-edited alleles, it does not enrich for off-target 
mutations. We note that GUIDE-Seq (Tsai et al., 2015) or similar would be required for whole 
genome examination of off-target cutting. 
CTS is an inexpensive, rapid, straightforward, and readily scalable method, conceptually 
analogous to other marker-assisted enrichment strategies (Arribere et al., 2014), which increases 
the likelihood of isolating cells bearing knock-in alleles and hence significantly accelerates the 
production of in vitro-based disease models. We encountered significant variability with inter-
locus targetability and suspect that local sequence composition and chromatin organization likely 
influences repair preference. Given the multifactorial nature of complex diseases and especially 
the role of modifier loci, we envisage CTS being of potential utility for simultaneous 
recapitulation of multiple candidate variants. Indeed, using CTS, we concurrently delivered 
editing reagents designed to incorporate mutations at two different loci and isolated multiple 
clones bearing both edits (Figure 4.7). It will be interesting to determine whether polycistronic 
sgRNA delivery systems (Cong et al., 2013) will permit highly parallelized HDR-based genome 
editing in conjunction with CTS.  
Operationally, CTS provides a marked improvement in the efficiency of isolating 
precision-modified iPSC lines compared with no selection/direct cloning, without extended 
hands-on time or a requirement for additional instrumentation. Following methodological 
refinements and legislating for effect-range, we conservatively estimate that a single well-trained 
technician could generate ten precision-edited cell lines in one month. CTS is also generalizable 
in that while the system described uses antibiotic resistance as the selectable modification, 
alternative HDR-based modifications (e.g., insertion of a GFP cassette) could theoretically be 










Figure 4.7: Simultaneous, dual modification using CTS. (a) Dual modification was 
attempted on hB53 hiPS6 using components for targeting MTERF4:c.693delATA and 
CRYAB:c.358 A>G. Following CTS, 50 clones were sequenced, and of those, 15 had knock-in 
at CRYAB (depicted in the red circle) and 6 had knock-in at MTERF4 (depicted in the blue 
circle). All 6 of the cells with MTERF4 knock-in also had knock-in at CRYAB. Given 
individual editing rates, the likelihood of co-occurrence assuming random distribution of 
events is 5%. We observed a disproportionate co-occurrence of dual modification with a 
FET<0.001. (b) Representative chromatograms of dual-targeted clones at each loci and wild-
type (WT) sequences. Black arrows indicate variant of interest position. Silent, engineered 
blocking mutations that prevent re-targeting by Cas9 are indicated by grey arrows. (c) Table 
including genotypes of individual clones at both (MTERF4 and CRYAB) loci. WT indicates 





user requirements. For example, knock-in of a GFP tag into a cardiac transcription factor such as 
NKX2-5 (Elliott et al., 2011) would yield iPSCs that harbor a variant of interest in tandem with a 
reporter which assists with cardiomyocyte isolation. Furthermore, compared to alternative knock-
in strategies facilitated by targeted insertion of a selectable marker, CTS does not require the 
production of gene-specific custom targeting vectors making it a readily scalable strategy. In 
addition, while we observed no adverse effects of AAVS1 targeting or carriage of the pac cassette 
on cell behavior or differentiation potential, (although appropriate control cell lines harboring 
only the pac cassette should be utilized for phenotypic evaluation), removal of the pac cassette 
could be performed through transfection of cells with piggyBac transposase. Finally, although we 
show utility of CTS in iPSCs for enhancing the efficiency of isolating HDR-modified clones, we 
envisage CTS being widely applicable mismatch repair-competent cell types. 
 
Experimental Procedures 
CRISPR target site design and plasmid construction 
CRISPR target sites proximal (within 35 bps) to the SNP of interest were identified using 
ZiFiT Targeter Version 4.2. Target sites as unique as possible – based on dissimilarity to other 
genomic loci - were selected (Table 4.4). Typically, sites were chosen that had zero or one “off by 
0” or “off by 1” matches elsewhere in the genome. pX330-U6-Chimeric_BB-CBh-hSpCas9 was a 
gift from Feng Zhang (Addgene plasmid # 42230). Reverse complementary oligonucleotide pairs 
with BbsI overhangs were purchased from Sigma (or Life Technologies) and hybridized, and 
cloned into the pX330 vector as described previously (Cong et al., 2013). 
 
Culture and transfection of HEK293T cells and Cel-1 surveyor assay 
HEK293T cells, maintained in Dulbecco’s modified Eagle medium (DMEM) with high 
glucose, sodium pyruvate and L-glutamine (Life Technologies) supplemented with 10% fetal 
bovine serum (FBS- Life Technologies) and 100 u penicillin/100ug streptomycin/ml media (P/S- 





Table 4.4 CRISPR guide RNA sequences 






validating cleavage efficiencies of designed CRISPR guides, HEK 293T cells were mixed with 
SF nucleofection solution (Lonza) and various pX330 plasmids and transfected with the 4D 
Nucleofector™ (Lonza) using program CM-130. Cells were harvested 48 h later and CRISPR 
activity was validated using the Cel-1 Surveyor assay as previously described (Geurts et al., 2009; 
Miller et al., 2007).  
 
ssODN design 
We typically designed ssODNs to flank the variant and/or cut-site by approximately 60bp 
on either side. In keeping with previous reports (Chen et al., 2011; Long et al., 2014; Paquet et 
al., 2016; Ponce de León et al., 2014), silent mutations were incorporated into the ssODNs to 
prevent re-cutting by Cas9 following HDR. This was achieved either through disruption of the 
PAM sequence or multiple disruptions within the target sequence. ssODNs utilized in 
experiments are shown in Table 4.5. 
 
AAVS1 targeting plasmids 
The AAVS1 Safe Harbor TALE-Nuclease kit was purchased from System Biosciences 
(SBI), including TALENs previously shown to have minimal off-target cleavage (Hockemeyer et 
al., 2011). Plasmids include the HDR donor vector, pAAVS1 Dual Promoter Donor Vector 
(GE602A-1) containing GFP-Puromycin resistance cassette driven by an EF1α promoter, and the 
TALE-Nuclease Vectors, pZT-AAVS1 L1 TALE-N Vector (GE601A-1) and pZT-AAVS1 R1 
TALE-N Vector (GE601A-1). These were used for all Illumina MiSeq experiments (except 





Table 4.5 ssODN sequences 









































BAG3:c.1402G>A, MTERF4:c.693delATA, and CRYAB:c.325G>C. A second AAVS1 Safe-
harbor kit was purchased from Transposagen (Puro-TK with XTN™ TALEN, Catalog # KSH-
004) with the donor vector that includes a puromycin resistance gene and thymidine kinase 
selection cassette driven by a PGK promoter and flanked by piggyBac repeats, which can be 
sequentially, seamlessly removed with excision by piggyBac transposase if desired, as well as the 
accompanying AAVS1-specific XTN Forward and Reverse TALEN nucleases. The Transposagen 
system was used for generating CRYAB:c.358A>G and CRYAB:c.343delT clones. Additionally, 
we designed and validated a sgRNA targeting the AAVS1 locus (guide RNA complementarity 
region (5’-3’) GTCACCAATCCTGTCCCTAG) cloned into pX330 as described above. This 
pX330-AAVS1 was used in concert with the AAVS1 donor vector from Transposagen for 








All human subject research was approved by the Medical College of Wisconsin and 
University of Utah Institutional Review Boards. The human iPSC lines used in this study are 
hB53 hiPS6 (Riedel et al., 2014), derived from a 25-year-old Caucasian male and hB119 hiPS9, 
derived from peripheral blood mononuclear cells of a healthy 34-year-old Caucasian male using a 
polycistronic lentivirus containing OCT4, KLF4, SOX2, and c-MYC as previously described 
(Riedel et al., 2014). Informed consent was obtained for this procedure. hB53 hiPS6 was used for 
generating cell lines with the following knock-in mutations: BAG3:c.1402G>A, 
BAG3:c.1430G>A, MTERF4:c.693delATA, CRYAB:c.358A>G, CRYAB:c.325G>C and 
CRYAB:c.343delT, as well as the dual targeting experiment. hB119 hiPS9 was used for 
generating the cell line containing LMNA:c.1346G>T. We successfully applied our CTS method 
to two other iPSC lines (data not shown): knocking-in CRYAB:c.358A>G and CRYAB:c.325G>C 
mutations into hB119 hips10 (an alternate iPSC line derived from the same individual as hB119 
hiPS9 using the same method, unpublished data) and reverting homozygous CRYAB:c.343delT to 
homozygous wildtype in a female iPSC line derived from the patient (Forrest et al., 2011), which 
was reprogrammed using retrovirus (Mitzelfelt et al., 2016). 
 
iPSC culture 
Prior to transfection, iPSCs were cultured as previously described (Mitzelfelt et al., 2016) 
in feeder-free conditions on Matrigel (Corning)-coated 6-well plates with mTeSR1 (Stem Cell 
Technologies) or StemMACS iPS-Brew XF (Miltenyi Biotec). Cells were passaged every 3-4 
days using Accutase (Life Technologies) and seeded in media containing 10μM Rho-associated, 








CTS for generation of knock-in iPSC lines.  iPSCs were pretreated for 3-4 h with 10μM 
ROCK inhibitor, washed once with Dulbecco’s phosphate buffered saline (DPBS- Life 
Technologies), and incubated with Accutase (Life Technologies) for 5-8 min. Wash medium 
(Knockout DMEM/F12 supplemented with 10% FBS- both from Life Technologies) was added 
and cells were pipette vigorously to generate a single cell solution and counted using a Countess 
Automated Cell Counter (Life Technologies). For each transfection (day 0), 1µg of the gene-
specific pX330 CRISPR/Cas9 plasmid, 2µl of a 40µM stock solution or 1.5μl of a 20µM stock 
solution of the relevant ssODN, 1µg of each of the two AAVS1-specific TALEN plasmids (or 1µg 
of the AAVS1-specific pX330 CRISPR plasmid) and 1µg AAVS1 donor plasmid (see Targeting 
Reagents above) were added to 100µl P4 solution (Lonza) and electroporated using program CB-
150 on a 4D Nucleofector™ into iPSCs (1x106 cells/transfection). Cells from each transfection 
were then seeded into one well of Matrigel-coated 24-well plate (5,000 cells/mm
2
) for recovery in 
mTeSR1 or StemMACS iPS-Brew XF supplemented with 10μM ROCK inhibitor. The following 
day (day 1), cells were washed once with DPBS to remove dead cells and media was changed to 
mTeSR1 or StemMACS iPSC-Brew XF. Two days post-transfection (day 2), iPSCs were 
dispersed using Accutase and distributed across a 6-well plate pre-seeded with Mitomycin C 
(SantaCruz) -treated SNL feeder cells (Cell Biolabs) in ESC medium, composed of Knockout 
DMEM (Life Technologies) supplemented with 20% Knockout Serum Replacement (Life 
Technologies), MEM-NEAA (Life Technologies), 2mM L-glutamine (Life Technologies), P/S, 
0.1mM β-mercaptoethanol (Sigma), 10ng/ml human basic fibroblast growth factor (bFGF, Cell 
Signaling), and 50ng/ml L-ascorbic acid (Sigma), supplemented with 10μM ROCK inhibitor. 
Media was changed two days later (day 4) to ESC medium minus ROCK inhibitor. Three days 
post-seeding (day 5), puromycin (0.5-1µg/ml)-supplemented ESC-conditioned media (ESC media 
conditioned on SNL feeder cells with bFGF and vitamin C added post-conditioning) was added 





puromycin selection limits the extent of selection for transient expression of puromycin resistance 
and selecting until picking ensures that all colonies picked have integration of the pac cassette. 
Following ~7-10 days of maintenance in puromycin-containing media (day 12-16), distinct 
colonies (~1mm diameter) were apparent and manually/mechanically transferred each to a single 
well of a 24-well plate pre-seeded with feeder cells in ESC media plus ROCK inhibitor. Half of 
each isolate was retained for expansion and half for DNA isolation to genotype. Following 
genotyping (see below), desired clones were passaged to single wells of 12-well matrigel-coated 
dishes in mTeSR1 plus ROCK inhibitor and further expanded for pluripotency 
immunocytochemistry and karyotyping (see below) and frozen for future culture in freezing 
medium composed of FBS plus 10% dimethyl sulfoxide (DMSO- Sigma). Isolated knock-in iPSC 
lines were frequently subcloned to ensure homogeneity of the population. 
Transfection and CTS for Illumina MiSeq experiments.  With the aim to assess the effect 
of our CTS regimen on editing outcomes, we carried out next-generation sequencing using the 
Illumina MiSeq platform via a pooled amplicon strategy, including 7 different variants of interest 
(Table 4.3) across 4 different genes (CRYAB, BAG3, LMNA and MTERF4,) in two different cell 
lines (hB53 hiPS6 and hB119 hiPS9). Samples were prepared as described above except, two 
days post-transfection (day 2), iPSCs were dispersed such that 10,000 iPSCs were allocated 
across 3 wells (Puro
-
) and the remainder across the other 3 wells (Puro
+
) of a 6-well plate. Media 
was changed every other day for 1 week (day 5-12) with or without puromycin, accordingly. 
Following 1 week maintenance (day 12), all three Puro
+
 wells and all three Puro
-
 wells were 
collected and combined separately. In order to deplete the feeder cell sub-population, cells were 
reseeded in one Matrigel-coated 6-well plate wells in mTeSR1 plus ROCK inhibitor. At 
confluence, cells were again dispersed, combined and pelleted for isolation of genomic DNA and 








Genotyping PCR and Sanger sequencing for clones 
To isolate genomic DNA from clones, 30μl Quick Extract Solution (Epicentre) was 
added to each cell pellet (half colony) and incubated for 15 min at 65°C, followed by 5 min at 
95°C. PCR was carried out using gene-specific primers (Table 4.6) and the resulting amplicons 
were PCR-purified using a PureLink Quick PCR Purification Kit (Life Technologies) and Sanger 
sequencing was performed by Retrogen (San Diego, CA) with the same primers used for 
amplification. Sequences were analyzed using Sequencher software. 
 
Illumina MiSeq library preparation  
Genomic DNA was isolated from cell pellets using a PureLink Genomic DNA Mini Kit 
(Life Technologies). Samples were prepared for analysis with Illumina MiSeq as previously 
described (Kistler et al., 2015). PCR 1 primers are listed in Table 4.7 with adapter sequences in 
red and green text for the forward and reverse primers, respectively. PCR2 was performed using 
the Nextera XT Index Kit (#15055293) from Illumina according to manufacturer’s instructions. 
Individual amplicons were quantified via qPCR (KAPA Biosystems) and pooled at 3nM 
concentrations. To ensure high sequencing quality, following pooling, final amplicon pools were 
quantitated by qPCR to determine the precise molarity of the pool as a whole. Samples were 
sequenced using Single read sequencing (250bp read) and dual indexing on an Illumina MiSeq 
following the manufacturer’s instructions. The pool was run with a 30% spike-in of Phi-X to 
avoid issues with low-complexity Amplicon Libraries. 
 
Illumina MiSeq analysis methods 
In all cases, reads were inspected using the FASTX-Toolkit to assess general quality and 
then 3’-clipped where the Q score in a 4 nucleotide sliding window fell below 15 and filtered as 
to retain only those of 100 nucleotides or longer using Trimmomatic (Bolger et al., 2014). 
Pipeline error rate was estimated by deep-sequencing unedited amplicons derived from each 








Table 4.6 Genotyping primers 













Table 4.7 Illumina MiSeq PCR 1 primers 

















(obtained from Ensembl release 84) with Bowtie2 and assessing sequence divergence in the 
informative segment (10 nucleotides up/downstream of the nucleotide to be mutated and the  
CRISPR PAM site) of each target read. Average coverage was ~240,000X and average sequence 
divergence from the reference at Q30 was 0.1%. For knock-in experiments, we quantified the 
extent of HDR-mediated donor integration by interrogating pre-processed FASTQ files (as 
described above) for informative segments of the donor sequence (typically ~50 nucleotides, 
spanning the targeted nucleotide and CRISPR cut site (not simply the targeted nucleotide, as this 
may occur in the presence of an indel and lead to overestimation of knock-in) using a Linux grep 
command (of format : grep -A 2 -B 1 ‘ssODN sequence’ ‘INPUT.FQ’ | sed '/^--$/d' > 
‘OUTPUT.FQ’) as well as via manual inspection of FASTQ files for confirmation. For 
comparative value, HDR was also quantified using the Church lab’s CRISPR Genome Analyzer 
(Güell et al., 2014) and we observed good agreement with our estimates (data not shown). 
 
PCR to confirm HDR at AAVS1 locus 
To confirm HDR at the AAVS1 locus, inside-out PCR was performed on all knock-in 
variant cell lines. Primers were designed for the SBI and Transposagen AAVS1 targeting vectors 
for both the 5’ and 3’ ends with one falling inside the homology arm (i.e., in the exogenous 
sequence) and one outside (i.e., in the endogenous locus) (Table 4.8) and PCR was performed 
with Accuprime Supermix II (Life Technologies).  
 
PCR to screen for random integration of the AAVS1 donor vector 
To screen for random integration of the AAVS1 donor construct, two sets of PCR primers 
were designed for each donor vector (SBI and Transposagen) that amplify the backbone region 
(i.e., the region of the vector outside of the homology arms) (Table 4.9). PCR was performed 
using Accuprime Supermix II (Life Technologies) with plasmid DNA as a positive control and 
DNA from hB53 hiPS6 and hB119 hiPS9 iPSCs as negative controls. Bands were undetectable in 








Table 4.8 Primers for confirming integration at AAVS1 
Name Primer Sequence (5’-3’) Expected PCR Product Size 
SBI 5’ Forward AGTCCGGACCACTTTGAGCTCTACT 
1061bp 
SBI 5’ Reverse GAGGAGTAGAAGGTGGCGCGAA 
SBI 3’ Forward AGGTTTAGCCCCGGAATTGACTG 
1036bp 
SBI 3’ Reverse CCAAAAGGCAGCCTGGTAGACA 
Transposagen 5’ Forward CTCTTTCCGGAGCACTTCC 
711bp 
Transposagen 5’ Reverse CCGATAAAACACATGCGTCA 
Transposagen 3’ Forward ACTTACCGCATTGACAAGCA 
805bp 




Table 4.9 Primers for screening for random integration of the AAVS1 vector 
Name Primer Sequence (5’-3’) 
Expected PCR Product 
Size 
SBI Random Forward 1 GTGCCACCTAAATTGTAAGCGTT 
495bp 
SBI Random Reverse 1 AACAGTTGCGCAGCCTGAAT 
SBI Random Forward 2 TGCTGCTGCATTGACGTTGA 
408bp 
SBI Random Reverse 2 TGCTTCCGGCTCGTATGTTG 
Transposagen Random Forward 1 GCTTCCTCGCTCACTGACTC 
409bp 
Transposagen Random Reverse 1 CGACCTACACCGAACTGAGA 
Transposagen Random Forward 2 CGGTGAAAACCTCTGACACA 
380bp 







knock-in experiments, 4 showed positive bands with the random integration primers indicating an 
approximate 10% rate of random integration of the AAVS1 donor vector.  
 
Immunocytochemistry 
Immunocytochemistry was performed as previously described (Mitzelfelt et al., 2016). 
Briefly, iPSCs were seeded onto 12mm glass coverslips in 12 well plates coated with Matrigel in 
mTeSR1 or StemMACS iPS-Brew XF supplemented with 10μM ROCK inhibitor. The following 
day, media was changed minus ROCK inhibitor and incubated for 4 h. iPSCs on coverslips were 
washed with DPBS, fixed with 4% paraformaldehyde at room temperature for 15 min, washed 
two times with DPBS, and stored in DPBS at 4°C until staining. Cells were permeabolized with 
0.1% triton-X 100 in DBPS for 10 min, washed once in DPBS, and blocked for 1 h at room 
temperature with 3% bovine serum albumin (BSA-Sigma) in DPBS. Primary antibody was added 
in 3% BSA/DPBS and incubated for 2 h at room temperature. Primary antibodies: Nanog (Cell 
Signaling 4903p, USA, 1:200) and stage-specific embryonic antigen-4 (SSEA-4) (Stem Cell 
Technologies 60062AD, USA, 1:40). Cells were washed three times with DPBS. Secondary 
antibody was added in DBPS and incubated for 1 h at room temperature. Secondary antibody: 
Alexa Fluor 555 donkey anti-rabbit IgG (A31572). Cells were washed three times and mounted 
with Ultracruz Hard Set Mounting Media plus DAPI (Santa Cruz). Representative images were 
taken using the inverted Nikon Eclipse TE 2000. 
 
Karyotyping 
Karyotyping, performed as previously described (Mitzelfelt et al., 2016), was carried out 
by Wisconsin Diagnostic Laboratories (formerly Dynacare Laboratories), Milwaukee WI. 
Chromosomes of 20 proliferating cells were counted and fully analyzed using G-banding with 







Potential off-target analysis 
Clone analysis.  Potential off-target sites were predicted by CRISPR RGEN Tools Cas-
OFFinder (Bae et al., 2014) and are shown in Table 4.10 (with lowercase text indicating 
mismatches from the guide sequence). We chose the top 3-5 off-target sites for each CRISPR  
guide and designed primers that amplify a 300-500bp region around the off-target site. Off-target 
genomic regions were amplified using Accuprime Supermix II in all isolated knock-in clones. 
Amplicons were PCR-purified using a PureLink Quick PCR Purification Kit and Sanger 
sequencing was performed by Retrogen in both the 5’ and 3’ directions with the amplification 
primers. Sequences were analyzed using Sequencher software. Sequencing results were compared 
with the originating cell line (either hB53 hiPS6 or hB119 hiPS9). No mutations were noted (data 
not shown). 
Illumina MiSeq analysis.  To ensure CTS does not enrich for off-target effects, we chose 
our most active CRISPR (targeting CRYAB), and analyzed the top 12 potential off-target sites by 
deep-sequencing using the Illumina MiSeq. CRISPR RGEN Tools Cas-OFFinder (Bae et al., 
2014) was used to identify potential off-target sites with sequences identified in Table 4.11 
(lowercase text indicates mismatches from the guide sequence). Primers were designed flanking 
these sites and samples were prepared and analyzed using the Illumina MiSeq (as described 
above). PCR 1 primers are listed in Table 4.11 (adapter sequences in red and green text for the 
forward and reverse primers, respectively). Reads were inspected and 3’-clipped as described 
above before being aligned to the appropriate off-target reference sequences using Bowtie2 (with 
the ‘local’ alignment setting to maximize the chance of finding indels). Resulting SAM files were 
converted to sorted/indexed BAM files and loaded into IGV for viewing. We found no 
measurable difference in indel presence between pooled populations following CTS compared to 





Table 4.10 Off –target sites screened by Sanger sequencing 
CRISPR Potential Off-Target Site Chromosome Position 
Primer 
Name 


































































































Table 4.11 CRYAB off-target sites analyzed by Illumina MiSeq 
Potential Off-
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DISCUSSION: HSPB5 IN MYOPATHY AND CTS CRITIQUE 
 
 
Mechanisms of HSPB5 in (Cardio-) Myopathy 
 
Chapter 3 presents molecular and biochemical data regarding 343delT HSPB5 protein 
dynamics (Mitzelfelt et al., 2016). Of interest, evidence for extreme insolubility of the mutant 
protein is evident and rescued by fusion with a SUMO moiety, a known solubilizing 
modification. Coexpression of 343delT with WT HSPB5 also solubilizes the mutant form of the 
protein. Insoluble 343delT is likely functionally unavailable, thereby supporting a loss of function 
disease mechanism. On a related theme, phenotypes of the HSPB2/HPSB5 double knockout 
mouse (DKO) (Brady et al., 2001) are neither as severe nor early-onset as the signs observed in 
the patient (Forrest et al., 2011). In addition, the mutant protein accumulates as dense, irregular 
deposits in the patient’s skeletal muscle biopsy (Forrest et al., 2011). This suggests a potential 
detrimental impact of the presence of the 343delT protein in disease progression. Indeed, 
overexpression of 343delT results in protein aggregates that can colocalize with the intermediate 
filament protein desmin and induce a cellular stress response indicating disruption of proteostasis 
(Mitzelfelt et al., 2016). These data suggest a model in which disease onset in the homozygous 
343delT state is initiated by lack of HSPB5 (i.e., loss of function) leading to an “at risk” muscle. 
Activation of cellular stress response pathways leads to transcriptional upregulation of HSPB5, 
and this combined with a potential “second-hit stress” results in accumulated, aggregated mutant 
protein that then may impose detrimental effects on the cell (i.e., gain-of-toxic function) resulting 
in accelerated disease progression and increased severity. This working model is outlined in 









Figure 5.1: Working Model for Potential Gain and Loss of Function Effects of 343delT in 
Myopathy. A.) The heterozygous 343delT parents, with one WT and one 343delT (denoted by 
the red star) allele are asymptomatic, as WT is available to perform essential functions and 
343delT is solubilized by WT. The homozygous recessive 343delT patient (B and C) can only 
produce 343delT protein. B.) Initially, 343delT protein is undetectable in the cells leading to loss 
of HSPB5 function that triggers increased susceptibility to stress, muscle deterioration with 
usage, and inability to properly regenerate muscle. In turn, cellular stress ensues. C.) As HSPB5 is 
a stress response gene, we hypothesize that stress-inducible upregulation in conjunction with a 
potential “second hit stress” are both necessary and sufficient to produce detectable levels of 
343delT protein, which is highly insoluble alone. Accumulation of 343delT protein aggregates in 
the cell resulting in gain-of-toxic function effects including perturbing the positive feedback 
stress loop and a deleterious cascade of events causing coaggregation with other metastable 
proteins including desmin, acting as a chaperone sink, and disrupting overall cellular proteostasis 






These data provide an example of potential mechanisms for a recessive mutant 
contributing to myopathy. The general principles may be applicable to other mutant forms of 
HSPB5, including dominant and recessive variants. Indeed, it has been suggested that the well-
studied variant, R120G, likely results in disease due to a combination of both loss and gain of 
function effects (Sanbe et al., 2011). Focusing only on variants that result in muscle (cardiac or 
skeletal) disease (reviewed in Chapter 1, Table 1.1) (Mitzelfelt and Benjamin, 2015), variability 
exists as to which tissue is affected, dominant or recessive presentation, and infantile or adult-
onset. The recessive mutants, 343delT and 60delC, result in infantile-onset, severe skeletal 
myopathy; whereas dominant mutations affecting either or both tissue types result in adult-onset 
symptoms. With only the present data, it is unknown if the now unaffected, heterozygous parents 
of the patients with the recessive mutations will exhibit symptoms due to the presence of the 
heterozygous mutation later in life. If this proves to be the case, a dominant inheritance pattern 
could also be suggested for these mutants, with the homozygous state resulting in enhanced 
susceptibility and increased severity. However, the ability of at least 343delT to be solubilized by 
its WT counterpart (Chapter 3) (Mitzelfelt et al., 2016), suggests that potential detrimental effects 
of the mutant may be ameliorated by the presence of the WT protein. 
 All but one of the (cardio-) myopathy-associated mutations in HSPB5 result in aberrant 
accumulation or aggregation of the mutant protein. The nonaggregating mutation, R157H, results 
in reduced binding efficacy to titin and likely has alternative disease mechanisms compared with 
the other mutations (Inagaki et al., 2006). It is possible that the aggregating mutants may follow a 
similar disease progression as predicted for 343delT in Figure 5.1. Dominant variants may result 
in adult-onset due to competition of the mutant protein with the WT form early in life (Andley et 
al., 2011; Perng et al., 2004; Vicart et al., 1998), while in the recessive state, infantile-onset likely 
results due to lack of WT. Reaching a threshold of mutant protein may be a common required 
theme among variants. As insoluble mutant protein levels surpass a threshold, a tipping point is 





The relative insolubility of the specific variant, its ability to be solubilized by WT HSPB5, and 
the presence or absence of WT (i.e., heterozygous or homozygous) likely contribute to the tipping 
point at which this threshold is breached. Once surpassed, the so-called gain-of-toxic function 
effects of the mutants ensue. The fact that HSPB5 is a stress response gene perpetuates the 
problem by creating a positive feedback loop where enhanced stress results in stress-inducible 
transcriptional upregulation of the mutant HSPB5, thereby producing more mutant protein in an 
already saturated system. Such protein aggregates are known contributors to disruption of 
proteostasis, functioning with a cascade effect, nucleating small aggregates that increase in size as 
additional meta-stable proteins and corresponding chaperones become sequestered within the 
aggregates, thereby enhancing the detrimental impact (McLendon and Robbins, 2011; Pattison et 
al., 2011; Wang et al., 2003; Wang and Robbins, 2006). Meta-stable components that are lost 
from the cytoplasm into the aggregates, and not resynthesized in a timely manner, likely 
contribute to myopathy through a loss of function mechanism (Yang and Hu, 2016; Yang et al., 
2014). 
 HSPB5 is a key component for skeletal muscle maintenance over time as is shown by the 
DKO mouse model, which displays progressive myopathy throughout life (Brady et al., 2001). 
Whereas the DKO mouse only exhibits cardiac defects when subjected to stress conditions 
(Morrison et al., 2004; Pinz et al., 2008). Though each tissue has some variability in 
protein/isoform expression, both cardiac and skeletal muscle likely benefit in a similar fashion 
from the chaperone function of HSPB5. A major difference between the tissues is the unique 
ability of skeletal muscle to undergo regeneration from resident progenitor (or satellite) cells. 
HSPB5 has also been shown to play critical roles in the differentiation of satellite cells into 
myotubes (reviewed in Chapter 1) (Mitzelfelt and Benjamin, 2015). This unique role of HSPB5 in 
progenitor cell differentiation may be a reason for heightened sensitivity of skeletal muscle in a 






 The apparent tissue specificity of the various mutations poses interesting questions as 
well. It is difficult to discern true tissue specificity from the small number of patients harboring 
these disease-causing mutations with undoubtedly variable lifestyles and genetic/epigenetic 
backgrounds. Only a snapshot of current events is available, without taking into account what 
might occur in the future or under specific conditions. Stress undergone by the tissue is 
unmistakably a factor affecting tissue susceptibility. In addition, the expression of potential 
modifier genes most likely affects outcomes. Future experiments using model systems that allow 
controlled comparisons would be required to determine true tissue specificity.  
 Many questions remain as to the contribution of HSPB5 disruption in (cardio-) 
myopathy. Chapter 6 discusses future experiments designed for further investigation into 
mechanisms and treatments for 343delT in myopathy in the form of a proposal. Studies involving 
343delT present a platform to provide a better understanding of how chaperones contribute to 
overall muscle homeostasis and how defects in chaperones contribute to disease. An 
understanding derived from these experiments will likely be adaptable to other systems.  
 
Genome Editing with CTS: Advantages, Disadvantages, and Future Studies 
 Vast progress has been made with genome engineering, especially over the last ten years, 
necessitating its use in many aspects of research. Protocol publications and key advancements 
will make this technology more available and less intimidating to the common laboratory. CTS 
(described in Chapter 4), provides an efficient, innovative but simple strategy for enhancing the 
isolation of precision-modified clones that makes disease-in-a-dish model production readily 
available to the common user for the following reasons (see Table 5.1 for comparison with other 
published strategies): 
• Simplicity- CTS requires only design of a gene-specific sgRNA and ssODN, not the 
design of an extensive targeting vector, which many laboratories that are less well versed 











Table 5.1: Comparison of CTS with previously published strategies 
 
Task or Quality NS TS Sib-selection CTS 
Hands on time for component 
design/generation (guide RNA 
and vector or ssODN) 
1 h 4 h 1 h 1 h 
Total time for preparing 






1 week 1 week 
Hands on time for transfection 
of iPSCs 
2 h 4 h 2 h 2 h 
Hands on time for sib-selection None None 8 h None 
Clone number to isolate >2000 10 10 10-50 
Hands on time for feeding cells 15-25 h 30 min 1 h 30 min 
Hands-on time for isolating and 
genotyping clones 
>100 h 4 h 1 h 4-6 h 
Total time required (from 
design-genotype) 
~3.5 weeks ~11-14 weeks ~3.5 weeks ~3.5 weeks 
Total hands-on time required ~122-132 h ~13 h ~13 h ~9 h 
Restrictiveness in targeting None 
Need a TTAA 
site 
None None 








Scarless Yes Yes Yes 
Can be 
adapted 
Technical difficulty Low Medium Medium Low 
Required additional equipment None None ddPCR None 
Adapted from Miyaoka and colleagues (Miyaoka et al., 2014). NS= no selection/direct cloning. 
TS= targeting with selection/ piggyBac system (Yusa et al., 2011). Sib-selection= digital droplet 






of additional equipment over conventional targeting. 
• Speed- CTS is a one-step editing process as opposed to other efficient two-step strategies 
that require subsequent removal of a selection cassette (Yusa, 2013; Yusa et al., 2011). 
CTS leave a selection cassette in a safe-harbor locus, which is an allowable and 
controllable presence for most research purposes, though not applicable for clinical use. 
• Efficiency- CTS provides marked enhancement of efficiency for the incorporation of 
variants of interest over no selection and transient selection for transfection. 
• Cost- CTS utilizes custom ssODNs, which are around 10-fold cheaper than custom 
targeting vectors and require less time for production. The upfront cost of purchasing the 
commercially available AAVS1 targeting vector/TALEN kit utilized in CTS is 
generalizable to all future editing experiments performed by the laboratory.  
• Scalability- Many genes can be targeted using the AAVS1 components for CTS in concert 
with easily designed and generated gene-specific CRISPR/Cas9 guide RNAs and 
ssODNs. 
 As discussed in Chapter 2, the future holds further advances in efficiency and specificity 
of genome editing for both laboratory and clinical applications. Though CTS is not the “one size 
fits all” solution to genome editing, it provides a straightforward alternative to other available 
strategies allowing the common user a method for time-efficient, inexpensive, simple, and 
scalable genome editing, which is critical for the further dissemination and widespread use of the 
technology. Coupling CTS with other strategies such as inhibition of NHEJ (Maruyama et al., 
2015), cell cycle synchronization (Lin et al., 2014), or delivery of targeting components as 
preassembled RNPs (Lin et al., 2014) will likely further enhance the efficiency of recovering 
HDR-modified clones. Additionally, alternative selection strategies to knock-in of the selection 
cassette at AAVS1 could be employed. For example, selecting for HDR by fluorescence activated 
cell sorting (FACS) through incorporation of a fluorescent marker, knock-in of a cell type-





would utilize the hypothesis of CTS, while altering the selection method. 
 The CTS hypothesis, selection for HDR at one locus enriches for HDR at a second locus, 
suggests that certain “receptive” cells are more amenable to genome editing than other 
“refractory” cells. Though the efficiency data presented in Chapter 4 support this hypothesis, the 
mechanism remains elusive. Receptivity could be a transient state, brought on by stage of the cell 
cycle, expression of components necessary for editing, cell stress status, age, etc. Alternatively, 
receptivity could be a permanent state, retained by certain cells within a culture. The implications 
of the latter suggest heterogeneity within the culture that could be selected for with multiple 
rounds of targeting. Though at first glance this is appealing, it presents further questions as to the 
status of these “super-editable” cells that may confound future work performed for phenotypic 
analysis, etc. This idea could be tested through subsequent rounds of CTS to determine if 
efficiency of editing is enhanced in a population of cells that previously underwent CTS. 
Additional work to elucidate mechanisms behind CTS would likely require the ability to single-
cell sort cells as they undergo the editing process to compare the cell cycle state, transcriptome, 
and proteome of receptive versus refractory cells in order to elucidate factors contributing to this 
HDR-receptive state. The ability to isolate and purify cells as they undergo editing is less well 
defined and warrants further investigation. 
 Extreme locus variability with respect to the efficiency of CTS was observed and is being 
actively investigated. Local sequence composition and chromatin organization likely affect both 
the ability of the SSN to bind and cleave DNA, as well as the repair pathway preference. It is 
difficult to generalize comparisons across loci due to the multitude of variables (e.g., sequence, 
chromatin state, etc.). Therefore, answers to these questions will require careful study design 
limiting variables in order to examine the impact of sequence, chromatin organization, and gene 
activity. Such studies must be performed over multiple loci. 
 An additional advantage of CTS is the ability to concurrently target multiple loci. Indeed, 





cassette at AAVS1, for a total of three HDR events occurring concurrently in one cell. 
Experiments attempting to incorporate three variants of interest (four total editing events) were 
met with poor cell viability, due potentially to an overload of DNA upon transfection, too much 
Cas9 protein (since each gene of interest’s sgRNA plasmid also contained Cas9 coding 
sequence), or overwhelming the cell with DSBs. Generation and use of plasmid arrays that 
include multiple sgRNAs and only one sequence for Cas9 may alleviate these issues making it 
efficient to target multiple loci simultaneously. This is important for the study of multifactorial 
diseases and modifier genes, where sequential editing of individual loci is time consuming and 
laborious. 
 Overall, CTS is an efficient, innovative but simple strategy for enhancing the isolation of 
precision-modified clones that is usable by a broad audience. Though it does not provide the 
magic bullet solution to genome editing efficiency, it does present a straightforward available 
solution making editing possible for a multitude of laboratories new to the field. Ease of use is 
key as genome editing quickly becomes a required technology for obtaining research funding for 




Andley, U.P., Hamilton, P.D., Ravi, N., and Weihl, C.C. (2011). A knock-in mouse model for the 
R120G mutation of alphaB-crystallin recapitulates human hereditary myopathy and cataracts. 
PloS One 6, e17671. 
 
Brady, J.P., Garland, D.L., Green, D.E., Tamm, E.T., Giblin, F.J., and Wawrousek, E.F. (2001). 
aB-Crystallin in lens development and muscle integrity: A gene knockout approach. IOVS 42, 
2924-2934. 
 
Forrest, K.M., Al-Sarraj, S., Sewry, C., Buk, S., Tan, S.V., Pitt, M., Durward, A., McDougall, M., 
Irving, M., Hanna, M.G., et al. (2011). Infantile onset myofibrillar myopathy due to recessive 
CRYAB mutations. Neuromuscular Disord. NMD 21, 37-40. 
 
Inagaki, N., Hayashi, T., Arimura, T., Koga, Y., Takahashi, M., Shibata, H., Teraoka, K., 
Chikamori, T., Yamashina, A., and Kimura, A. (2006). Alpha B-crystallin mutation in dilated 






Lin, S., Staahl, B.T., Alla, R.K., and Doudna, J.A. (2014). Enhanced homology-directed human 
genome engineering by controlled timing of CRISPR/Cas9 delivery. eLife 3, e04766. 
 
Maruyama, T., Dougan, S.K., Truttmann, M.C., Bilate, A.M., Ingram, J.R., and Ploegh, H.L. 
(2015). Increasing the efficiency of precise genome editing with CRISPR-Cas9 by inhibition of 
nonhomologous end joining. Nat. Biotech. 33, 538-542. 
 
McLendon, P.M., and Robbins, J. (2011). Desmin-related cardiomyopathy: an unfolding story. 
Amer. J. Phys. Heart Circ. Phys. 301, H1220-H1228. 
 
Mitzelfelt, K.A., and Benjamin, I.J. (2015). Multifunctional roles of αB-crystallin in skeletal and 
cardiac muscle homeostasis and disease. In The Big Book on Small Heat Shock Proteins, R.M. 
Tanguay, and L.E. Hightower, eds. (Springer International Publishing), pp. 269-299. 
 
Mitzelfelt, K.A., Limphong, P., Choi, M.J., Kondrat, F.D.L., Lai, S., Kolander, K.D., Kwok, W.-
M., Dai, Q., Grzybowski, M.N., Zhang, H., et al. (2016). Human 343delT HSPB5 chaperone 
associated with early-onset skeletal myopathy causes defects in protein solubility. J. Biol. Chem. 
291, 14939-14953. 
 
Miyaoka, Y., Chan, A.H., Judge, L.M., Yoo, J., Huang, M., Nguyen, T.D., Lizarraga, P.P., So, P.-
L., and Conklin, B.R. (2014). Isolation of single-base genome-edited human iPS cells without 
antibiotic selection. Nat. Meth. 11, 291-293. 
 
Morrison, L.E., Whittaker, R.J., Klepper, R.E., Wawrousek, E.F., and Glembotski, C.C. (2004). 
Roles for αB-crystallin and HSPB2 in protecting the myocardium from ischemia-reperfusion-
induced damage in a KO mouse model. Amer. J. Phys. Heart Circ. Phys. 286, H847-H855. 
 
Pattison, J.S., Osinska, H., and Robbins, J. (2011). Atg7 induces basal autophagy and rescues 
autophagic deficiency in CryABR120G cardiomyocytes. Circ. Res. 109, 151-160. 
 
Perng, M.D., Wen, S.F., van den, I.P., Prescott, A.R., and Quinlan, R.A. (2004). Desmin 
aggregate formation by R120G alphaB-crystallin is caused by altered filament interactions and is 
dependent upon network status in cells. Mol. Biol. Cell 15, 2335-2346. 
 
Pinz, I., Robbins, J., Rajasekaran, N.S., Benjamin, I.J., and Ingwall, J.S. (2008). Unmasking 
different mechanical and energetic roles for the small heat shock proteins CryAB and HSPB2 
using genetically modified mouse hearts. FASEB J. 22, 84-92. 
 
Sanbe, A., Marunouchi, T., Yamauchi, J., Tanonaka, K., Nishigori, H., and Tanoue, A. (2011). 
Cardioprotective effect of nicorandil, a mitochondrial ATP-sensitive potassium channel opener, 
prolongs survival in HSPB5 R120G transgenic mice. PloS One 6, e18922. 
 
Vicart, C.A., Guicheney, P., Li, Z., Prévost, M.C., Faure, A., Chateau, D., Chapon, F., Tomé, F., 
Dupret, J.M., Paulin, D., et al. (1998). A missense mutation in the alphaB-crystallin chaperone 
gene causes a desmin-related myopathy. Nat. Gen. 20, 92-95. 
 
Wang, X., Klevitsky, R., Huang, W., Glasford, J., Li, F., and Robbins, J. (2003). AlphaB-
crystallin modulates protein aggregation of abnormal desmin. Circ. Res. 93, 998-1005. 
 






Yang, H., and Hu, H.-Y. (2016). Sequestration of cellular interacting partners by protein 
aggregates: Implication in a loss-of-function pathology. FEBS J., ahead of print. 
 
Yang, H., Li, J.-J., Liu, S., Zhao, J., Jiang, Y.-J., Song, A.-X., and Hu, H.-Y. (2014). Aggregation 
of polyglutamine-expanded ataxin-3 sequesters its specific interacting partners into inclusions: 
Implication in a loss-of-function pathology. Sci. Rep. 4, 6410. 
 
Yusa, K. (2013). Seamless genome editing in human pluripotent stem cells using custom 
endonuclease–based gene targeting and the piggyBac transposon. Nat. Prot. 8, 2061-2078. 
 
Yusa, K., Rashid, S.T., Strick-Marchand, H., Varela, I., Liu, P.-Q., Paschon, D.E., Miranda, E., 
Ordonez, A., Hannan, N.R.F., Rouhani, F.J., et al. (2011). Targeted gene correction of α-














Myofibrillar myopathy describes a heterogeneous group of diseases resulting from 
malfunctioning muscle fibers, of which a subclass is caused by mutant protein chaperones. 
Multiple mutations in HSPB5 (CRYAB or αB-crystallin) have been identified with both 
congenital-onset and adult-onset skeletal myopathy. HSPB5 is a small molecular-weight heat 
shock protein that functions as a chaperone for client substrates including desmin, titin, and actin. 
HSPB5 also impacts differentiation of skeletal muscle progenitor cells affecting proliferation, cell 
cycle exit, levels of the muscle-regulatory factor MyoD, and modulation of RNA-induced 
silencing complex (RISC) activity. A patient harboring the homozygous recessive, nonsense 
mutation, 343delT in HSPB5 has been reported with symptoms and signs of severe congenital 
myopathy including extreme muscle stiffness and degeneration following normal development. 
The patient’s muscle biopsy shows dense, irregular staining of 343delT consistent with 
aggregation observed in culture upon overexpression, which also induces a cellular stress 
response and stochastically incorporates the intermediate protein desmin. The patient’s 
presentation also has similarities to the HSPB5/HSPB2 double knockout mouse, though the 
mouse seems to have less severe and later onset muscle deterioration. Therefore, the question as 
to whether this disease pathology results from loss of HSPB5 function and/or gain-of-toxic 
function of 343delT HSPB5 remains and whether this impact is seen in myogenic progenitor cells 
and/or differentiated myotubes. Clinical disease manifestation is likely multifactorial, stochastic, 





This chapter outlines future directions for the study of 343delT including both in vitro 
human cell culture models and in vivo rat models to define loss and gain of function effects of the 
mutation and is written in the form of a proposal. It builds upon preliminary studies of 343delT 
presented in Chapter 3 and utilizes genome editing techniques outlined in Chapter 4. The 
underlying hypothesis being tested is that mutant chaperones result in myopathy not only due to a 
loss of function mechanism but that aggregation of the mutant protein itself exacerbates disease 
severity and progression and that principal defects in muscle progenitor cells contribute to the 
inability of damaged muscle to sufficiently repair itself. The future experiments presented in this 
chapter can be divided into the following two major aims as outlined in Figure 6.1: 
 
Aim 1: Modeling disease-causing HSPB5 343delT-associated  
congenital myopathy in human iPSCs.  
Human iPSCs will be used to model HSPB5 343delT congenital myopathy as well as 
knockout of HSPB5 in vitro through differentiation to skeletal myotubes (iSKMs).  
Aim 1.1.  Phenotypic analysis of iSKMs will be performed including examination of 
aggregation, sarcomere and cellular breakdown, titin disruption, as well as changes in gene 
expression. Exogenous stressors will be supplied to provoke phenotypes that may not be visible 
in 2D static cultures.  
Aim 1.2.  Skeletal muscle progenitor cells will be isolated and analyzed for defects in 
proliferation, cell cycle exit, differentiation, and gene expression with response to cellular injury 
in vitro and transplanted in vivo. Successful completion of this aim will provide a platform for the 
study of congenital myopathies in vitro.  
 
Aim 2: Modeling disease-causing HSPB5 343delT-associated congenital  
myopathy using genetically engineered rats  
To promote this research for translation into humans, genetically engineered rat models 














Figure 6.1 A schematic representation of aims for future directions. Aim 1 involves the 
study of 343delT disease pathogenesis using iPSCs derived from the patient and an unaffected 
individual. Founding iPSC lines will undergo genome editing generating two separate cohorts 
of isogenic cell lines for direct comparisons. iPSC-derived skeletal myotubes (iSKMs) and 
myogenic progenitor cells will be studied in subaims 1.1 and 1.2, respectively. Aim 2 
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in rats through histopathology, serum creatine kinase levels, and examination of muscle strength. 
Successful completion of this aim will provide a complementary system to the in vitro human 
iPSC model described in Aim1 with an in vivo model system in Aim 2, in which the defects in 




 Myofibrillar myopathy (MFM), or muscle weakness caused by malfunctioning muscle 
fibers, results from a disruption in sarcomere structure. Mutations in genes that are important in 
myofibrillar structure, including desmin, filamin-C, and myotilin, as well as mutations in genes 
encoding chaperones, including HSPB5, have been associated with MFM. Molecular chaperones 
are essential in the regulation of protein quality control, through binding of unfolded/misfolded 
proteins, allowing them the opportunity to refold or be marked for degradation rather than 
accumulate as potentially pathogenic aggregates. The small molecular-weight heat shock protein, 
HSPB5 (aka CRYAB or αB-crystallin), functions as a molecular chaperone and has genomic 
enhancer regions that allow for tissue-specific expression in the lens, heart, and skeletal muscle 
(Swamynathan and Piatigorsky, 2007). HSPB5 acts as a chaperone for the muscle contractile 
proteins desmin (Bennardini et al., 1992), titin (Golenhofen, 2002), and actin (Bennardini et al., 
1992). Many different mutations in HSPB5 have been linked to multisystem disorders including 
cataracts, cardiomyopathy, and myopathy (Sacconi et al., 2012). These different mutants have 
variable penetrance and expressivity, are dominant or recessive, exhibit tissue-specific effects, 
and many are aggregation prone. The well-studied, dominant R120G mutation (Vicart et al., 
1998) promotes the aggregation of the intermediate filament protein desmin, among others, which 
contributes to the disease pathology (Perng et al., 2004). Whereas dominant mutations in HSPB5 
typically show progressive symptoms later in life (Sacconi et al., 2012; Vicart et al., 1998), 





result in early-onset, more severe conditions during infancy, termed congenital myopathy. 
The Benjamin Laboratory has extensively characterized the biological and functional 
roles of mutant HSPB5 in experimental animal models, including mice (Rajasekaran et al., 2007; 
Rajasekaran et al., 2008; Rajasekaran et al., 2011) and Drosophila (Xie et al., 2013), and in vitro 
cell culture models, including H9C2 cells and neonatal rat cardiomyocytes (Banerjee Mustafi et 
al., 2014; Zhang et al., 2010), as well as induced pluripotent stem cell (iPSC) models (Limphong 
et al., 2013; Mitzelfelt et al., 2016). Because the mechanisms of disease pathogenesis for mutant 
HSPB5 congenital myopathy in humans are poorly understood, interest is focused on the human 
343delT that results in the protein modification S115fs129X. This deletion causes a frameshift 
resulting in a large C-terminal deletion of HSPB5 (Forrest et al., 2011), removing a portion of the 
highly conserved α-crystallin domain and the C-terminus, critical for dimer stabilization (Hilton 
et al., 2013). An infant, female patient harboring this rare, homozygous recessive mutation born 
from unrelated, heterozygous parents presented initially at age 4 months following normal 
development with severe skeletal muscle stiffness, persistent creatine kinase elevation, and a 
muscle biopsy indicative of myofibrillar myopathy so severe that ventilation is required to sustain 
life (Forrest et al., 2011). The skeletal muscle biopsy shows dense, irregular staining of HSPB5 in 
the myofibers and western blot shows the presence of a truncated form of the protein (Forrest et 
al., 2011). Additionally, previous work has suggested a role for HSPB5 in skeletal muscle 
progenitor proliferation and differentiation (Neppl et al., 2014; Singh et al., 2010). 
Mitzelfelt et al. demonstrated that the 343delT protein is extremely insoluble and likely 
unavailable to perform normal cellular functions (see Chapter 3) (Mitzelfelt et al., 2016). 
Whereas the autosomal recessive mutation manifests myopathy, both heterozygous 
nonconsanguineous parents are phenotypically normal for known signs and symptoms of disease 
(Forrest et al., 2011), suggesting that the patient’s clinical presentation may be at least either 
partly due to loss of HSPB5 function or that genetic modifiers and other factors mitigate the 





(DKO) mouse, which exhibits progressive muscle deterioration over time (Brady et al., 2001). 
The aggregation potential of 343delT in cell culture models (Mitzelfelt et al., 2016) and the 
patient muscle biopsy (Forrest et al., 2011) as well as 343delT’s ability to coaggregate with 
desmin and induce a cellular stress response (Mitzelfelt et al., 2016) raise the intriguing 
possibility that 343delT may have some gain-of-toxic function effect causing symptoms observed 
in the patient to appear more severe compared with the DKO mouse. 
 
Goals 
This proposal aims to address the mechanisms for the relative loss and gain of function 
effects of 343delT in congenital myopathy. The proposed novel and innovative approaches for 
modeling 343delT-associated congenital myopathy using both in vitro (Aim 1) and in vivo (Aim 
2) systems will provide a general platform for detailed mechanistic and functional studies. 
Modeling cell-autonomous disease using a patient’s own iPSCs cells offers the potential for drug 
screening, possible cell-based therapies, or both. To mitigate the limitations of 2D culture, an in 
vivo rat model is both necessary and sufficient for disease recapitulation, required for testing 
future treatments. 
 
Specific Aim 1: Modeling Disease-causing HSPB5 343delT-Associated 
Congenital Myopathy in Human iPSCs 
Aim 1.1: iPSC model generation and phenotypic characterization 
Rationale.  This aim is high-risk since to date it has been difficult to model stress-
dependent protein aggregation diseases in iPSCs. HSPB5 is expressed at high levels in mature 
muscle where it plays a key role as a chaperone for cytoskeletal and contractile proteins 
(Bennardini et al., 1992; Golenhofen, 2002). Loss of this chaperone function and/or the presence 
of the 343delT mutant form of HSPB5 may contribute to the severe, congenital myopathy 
observed in the patient (Forrest et al., 2011). In this aim, 343delT-induced myopathy will be 





will be compared with HSPB5 knockout cells, to define phenotypes and determine whether 
phenotypes are due to loss or gain-of-toxic function of 343delT, providing insight into the 
requirement for HSPB5 in skeletal muscle maintenance. If successful, this model system will be 
highly useful for studying mechanisms driving MFM associated with chaperone dysfunction.  
Methods.  Genome engineering of mutant and control cell lines will be/has been 
performed using a novel gene editing strategy that markedly enhances one’s ability to isolate 
modified clones, cotargeting with selection (CTS) (Chapter 4) (outlined in Figure 6.2). The CTS 
hypothesis is that selection for homology-directed repair (HDR)-competent cells through 
incorporation of a primary selectable event will enrich for an HDR-mediated modification at a 
second locus. Proposed iPSC lines are outlined in Figure 6.3, a majority of which were generated 
previously. One iPSC line derived from the female 343delT patient (Pt), previously generated by 
the Benjamin Laboratory (Mitzelfelt et al., 2016), and one iPSC line from an independent, 
unrelated, unaffected male, hB53 hiPS6 (Riedel et al., 2014) (unaffected- UA), will be used along 
with gene edited versions of all lines to generate 2 separate isogenic sets of cells lines that are 
WT, heterozygous and homozygous for 343delT. To generate knockout of HSPB5, two guide 
RNAs will be designed using ZiFiT Targeter Version 4.2 to target upstream of the transcriptional 
start site and within the 3’ untranslated region. Guides will be transfected together so as to 
retrieve clones with the entire gene removed. This strategy to generate a complete knockout is 
proposed as opposed to targeted disruption early in the gene since even with very early 
truncations of HSPB5 (Del Bigio et al., 2011), protein is visible and may or may not impact 
disease. Per the CTS protocol, cells are transfected with components for targeting AAVS1 and 
HSPB5 simultaneously (Figure 6.2) and selected with puromycin for 10 days prior to manually 
picking and screening by Sanger sequencing of HSPB5 (Figure 6.3). Confirmation of HSPB5 
deletion will be initially screened for with PCR and confirmed by Southern Blot followed by 
western blot to confirm loss of the protein. Many of the proposed iPSC lines have been 













Figure 6.2: Cotargeting with selection (CTS) gene editing strategy (Chapter 4). 
Modification of the AAVS1 and HSPB5 loci will be performed simultaneously. The primary, 
selectable modification utilized is incorporation of a puromycin selection cassette (Puro
R
) 
into the AAVS1 safe-harbor locus using a commercially available system (Transposagen, 
SKU: AAVS-P-TALEN), while the secondary modification utilizes CRISPR/Cas9 along 
with a single strand oligonucleotide (ssODN) as a repair template to incorporate/correct 
HSPB5 343delT. Selection of the primary modification allows for enrichment of the 












Figure 6.3: Proposed iPSC lines to use for Aim 1 studies. Patient-derived (Pt) - and 
unaffected (UA) cell lines already generated and others to be generated are labeled in black 
and red text, respectively. Bold indicates founding cell lines for which gene editing was/will 
be performed. KI (knockin) indicates cell lines made with genetic knockin of either the WT 






iPSC lines are characterized for pluripotency and screened for genomic stability prior to 
differentiation as described below (Mitzelfelt et al., 2016). 
iPSCs will be differentiated to skeletal myotubes (iSKMs) as previously described 
(Mitzelfelt et al., 2016) using the EZ sphere protocol (Hosoyama et al., 2014). This differentiation 
approach generates both muscle progenitor cells as wells as multinucleated skeletal myotubes 
(iSKMs) (Figure 6.4). A range of phenotypic assays will be performed to fully characterize 
iSKMs. Initial assays will be performed in the cell lines derived from Pt-homo (i.e., homozygous 
mutant, heterozygous mutant, WT, and knockout) for optimization and assessment of differences 
to determine feasibility. Assays will then be repeated using the additional cell lines derived from 
UA-WT. In previously generated iSKMs (Pt-homo, Pt-het KI, Pt-WT KI, UA-homo KI), mutant 
protein (15kDa) is undetectable by either western blot or immunocytochemistry, while the WT 
protein (22kDa) is detected (Chapter 3, Figure 3.2) (Mitzelfelt et al., 2016). A series of detailed, 
mechanistic experiments shows that extreme insolubility of the mutant protein is the reason for 
lack of detection prompting the conclusion that insoluble 343delT would likely be unavailable to 
perform essential, normal functions of HSPB5 and therefore, loss of function is a factor likely 
contributing to disease (Chapter 3) (Mitzelfelt et al., 2016). In the patient biopsy, dense, irregular 
staining of 343delT is visible, suggesting that the presence of the mutant protein may contribute 
to disease. To this end, visible cytoplasmic aggregates containing the mutant protein that appear 
to stochastically incorporate desmin are visible upon overexpression of the mutant protein 
(Mitzelfelt et al., 2016). Aggregates also induce a cellular stress response (i.e., HSP70 induction), 
indicative of disruption of proteostasis (Mitzelfelt et al., 2016). Assays described in this proposal 
aim to determine the mutant protein’s relative loss and gain-of-toxic function contribution to 
disease. 
Mutant protein has proven undetectable at basal levels. Therefore, a series of 
experimental manipulations to invoke its detection will be employed providing a platform to 















Figure 6.4: iPSC-derived myogenic cells generated with the EZ sphere protocol. A.) EZ 
spheres at 6 weeks of suspension culture. B.) iSKMs after 27 days of terminal dissociation. 
C.) Pax7 immunostaining showing the presence of myogenic progenitor cells in cultures 
after 4 days terminal differentiation. D.) α-actinin immunostaining in day 21 iSKMs. 
Immunostaining merged with DAPI. 









resulting from loss of HSPB5 function, which will be evident in HSPB5 knockout cell lines. A 
suspected threshold exists with which the level of the mutant must surpass to reach detectable 
levels within cells, as with overexpression 343delT protein is detectable. We hypothesize that 
surpassing this threshold may trigger a cascade of events that results in the overall disruption of 
cellular proteostasis and contributes to muscle breakdown/dysfunction (please see Discussion in 
Chapter 5). The recently described CRISPR/Cas9 system with catalytically inactive Cas9 (dCas9) 
fused to transcriptional activators VP64-p65-Rta (VPR)(Chavez et al., 2015) along with guide 
RNA that recognize regions of the HSPB5 proximal promoter/enhancer will be used to upregulate 
endogenous HSPB5. This system for upregulation of HSPB5 has been validated in iPSC through 
qRT-PCR (Figure 6.5). Next steps are to validate protein level increases by western blot and to 
examine for the presence of aggregates with immunocytochemistry. iSKMs will be transfected at 
day 25 of differentiation (multinucleated iSKMs) using TransIT-LT1 transfection reagent (Mirus 
Bio) and examined 36-48 h later for expression of HSPB5 at the RNA (qRT-PCR) and protein 
(western blot and immunocytochemistry) levels. The presence/level of other meta-stable proteins 
within the cell may be required for nucleation of the aggregation process, as with stress, meta-
stable proteins are prone to unfolding. Transfection of a desmin containing plasmid (Addgene 
plasmid #54059) and/or use the dCas9-VPR system with guide RNAs generated to bind to the 
Desmin promoter to upregulate the metastable protein desmin within iSKMs as a stress on 
proteostasis will also be performed. Additional stressors include rapid, electrical pacing 
performed as described previously (Riedel et al., 2014) and calcium overload using a calcium 
ionophore (Malinska et al., 2010; Verma et al., 2011). In this way endogenous aggregation of 
343delT and its overall impact on cell structure and function will be examined. 
Phenotypic analysis will be performed with and without stressors described above and includes 
(described in more details below) sarcomere breakdown, titin aggregation (stiffness), cellular 
breakdown, and changes in gene expression. Sarcomere breakdown will be scored by 















Figure 6.5: Upregulation of HSPB5 with dCas9-VPR. Four guide RNAs (gRNA) 
recognizing the promoter region of HSPB5 were pooled together and transfected in increasing 
amounts (0, 50, 100, 200 ng) with dCas9-VPR in iPSCs. Approximately 4-fold enhanced 
expression was observed, which is an underrepresentation of individual cell effects due to 












































elastic protein in muscle that contains spring-like immunoglobulin (Ig) domains, for which 
HSPB5 is a chaperone (Bullard et al., 2004; Golenhofen et al., 2002; Golenhofen et al., 2004), 
that unfold and allow contracted muscle to stretch (Minajeva et al., 2001; Rief, 1997). If left 
unchecked, the Ig domains can aggregate and result in muscle stiffness (Kotter et al., 2014). As 
congenital myopathy patients associated with recessive HSPB5 mutations show profound muscle 
stiffness, titin will be analyzed through immunostaining and electron microscopy with 
immunogold labeling of titin and HSPB5. Enzyme-linked immunosorbent assay (ELISA) will be 
used to determine the level of human skeletal muscle α-actinin (kit from MyBioSource) in the cell 
culture media as a readout of cellular breakdown. Additionally, qRT-PCR on a panel of stress 
response genes will be performed to determine differences between cell lines. Overall, this 
phenotypic analysis in conjunction with the proposed stressors will likely evoke a pathological 
phenotype in iSKMs providing an in vitro disease model of congenital myopathy where 
histopathological abnormalities observed in the patient are the result of accumulated cellular 
stress. 
Expected results and interpretation.  It is expected that cell lines expressing 343delT may 
show a range of phenotypes indicating the “loss of function” effects of 343delT and others 
indicating “gain of function” effects of 343delT or partial 343delT function. Upregulation of 
HSPB5 using the dCas9-VPR system is expected to result in detectable aggregates of 343delT 
that will be further analyzed in future experiments. Sarcomere breakdown, titin aggregation, and 
elevated levels of media α-actinin is expected in homozygous 343delT cells that is more severe 
than knockout cell lines, while heterozygous 343delT cells will likely behave similarly to WT. 
Global changes in gene expression of stress response genes are anticipated, as homeostasis is 
disrupted. 
Possible pitfalls and alternative approaches.  If the proposed stressors do not result in 
visible aggregation of 343delT, iSKMs can be transfected with a plasmid expressing the 343delT 





transfection efficiency is too low with TransIT-LT1 (Mirus Bio), viral vectors and viruses will be 
generated and used as an alternative approach. Additional aggregation prone proteins highly 
studied in neurodegenerative diseases, including tau and poly-glutamine (Guerreiro et al., 2015; 
Seidel et al., 2016), could be transfected into cells as well to stimulate aggregation. Aggregation 
of titin may require cellular stretch, in which case devices that incorporate static stretch could be 
employed (Nguyen et al., 2013). 
 
Aim 1.2: Examine the impact of mutant HSPB5 on muscle progenitor  
cell proliferation and differentiation 
Rationale.  HSPB5 affects not only differentiated, mature muscle, but also plays a role in 
the muscle progenitor cell during differentiation (Singh et al., 2010). Proliferating myoblasts must 
turn off expression of the master regulatory transcription factor, MyoD, exit the cell cycle, turn on 
myogenin, and fuse to form multinucleated myotubes (Weintraub, 1993). When HSPB5 is 
overexpressed in C2C12 myoblasts, MyoD levels are lower in the myoblast and cell cycle exit is 
delayed, both negatively impacting differentiation to myotubes (Singh et al., 2010). DKO mice 
have a significantly reduced number of satellite cells in their skeletal muscle and a reduced ability 
to regenerate muscle following cardiotoxin-induced injury, indicating a potential role for HSPB5 
in skeletal muscle regeneration (Neppl et al., 2014). Neppl and colleagues show that in the 
absence of HSPB5, Argonaute2, a key component of the RNA-induced silencing complex (RISC) 
has significantly reduced activity affecting the proliferation/differentiation capacity of skeletal 
muscle progenitor cells (Neppl et al., 2014). In this aim, myogenic progenitor cells will be 
isolated from early iSKM cultures and analyzed for proliferation and differentiation capacity in 
vitro and in vivo to determine relative impact of gain and loss of function. This analysis will 
evaluate the requirement for HSPB5 in skeletal muscle differentiation.  
Methods.  EZ sphere cultures will be generated as described in Aim 1.1 and muscle 





with an antibody to the surface marker α7-integrin (Pawlikowski et al., 2009). α7-Integrin is also 
present on myotubes, but progenitors and myotubes can likely be differentiated by size and 
granularity (forward scatter and side scatter). Cells will be cultured in vitro stimulating 
spontaneous differentiation to myotubes with and without cardiotoxin (Demonbreun et al., 2010; 
Langone et al., 2014) to observe an injury response. Cell-cycle analysis will be performed by 
propidium iodide staining and visualized by flow cytometry on samples harvested at various time 
points to see if 343delT and/or HSPB5 knockout cells exit from the cell cycle at different time 
points compared with control. Proliferative potential of progenitor cells will be measured by co-
staining with Ki67 and MyoD followed by counting the number of double positive cells at 
different time points after sorting. MyoD mRNA and protein levels will be analyzed by qRT-PCR 
and western blot, respectively, to determine if temporal expression is altered. 
Immunocytochemistry costaining will be performed at different time points of differentiation 
with markers of progenitors, Pax7 and MyoD, or markers for more mature myotubes, α-actinin or 
myogenin, to characterize HSPB5 expression throughout the differentiation process.  
In parallel, a less biased approach will be undertaken to determine differences in gene 
expression between 343delT, knockout, and control cells. To this end RNAseq and small RNA-
seq, including microRNAs, will be performed on isolated progenitor cells cultured in vitro with 
and without cardiotoxin injury. Candidate factors of interest will be validated by qRT-PCR. 
In vitro injury response of progenitor cells will likely not fully recapitulate in vivo 
conditions. For this reason, isolated muscle progenitor cells from 343delT, knockout and WT 
iPSC lines will be injected into the tibialis anterior muscles of NOD/SCID gamma-c (NSG) mice 
(Shultz et al., 2005), with cardiotoxin injury as previously described (Darabi et al., 2012). Two 
months after transplantation muscle sections will be harvested and evaluated for engraftment by 
immunostaining with pandystrophin and human-specific dystrophin antibodies as previously 
described (Darabi et al., 2012). The percentage of fibers expressing human dystrophin will be 





Expected results and interpretation.  HSPB5 knockout progenitors are expected to exit 
the cell cycle at faster rates than controls, which would be shown by an increased number of 
knockout cells compared with control in the G0 state at earlier time points following sorting. 
Knockout cells may also show less Ki67-positive cells, indicating lower proliferative potential. 
MyoD levels may be altered in knockout cells compared to control. MyoD may turn on earlier or 
stay on longer due to the loss of function hypothesis, which would be consistent with the previous 
report showing delayed MyoD expression due to overexpression of HSPB5 (Singh et al., 2010). 
These results would indicate that loss of HSPB5 expression has an impact on proliferation and 
differentiation of myogenic progenitors to myotubes. Novel genes, including microRNAs whose 
expression is affected by loss of HSPB5 will be identified with the unbiased RNAseq. 343delT is 
expected to exhibit the same defects as knockout cells, which would indicate that this phenotype 
is likely due to loss of function effects of 343delT. Gain of function effects of 343delT due to 
aggregation are expected to manifest in mature muscle where expression levels of HSPB5 are 
higher, not necessarily in the progenitor cell state. With in vivo injection of human progenitor 
cells into mice, HSPB5 knockout cells are expected to account for a lower percentage of 
regenerated muscle fibers as compared with control cells, indicative of decreased regenerative 
capacity in the absence of HSPB5. 343delT progenitor cells are predicted to behave similarly to 
knockout cells in this assay. 
Possible pitfalls and alternative approaches. α7-Integrin may not be specific enough to 
identify the myogenic progenitor population of interest. Myomaker, a surface protein required for 
myoblast fusion, is another surface marker that could potentially be used to isolate progenitor 
cells (Millay et al., 2013). Additional surface markers could be used to deplete other cells in the 
culture. Alternatively, a lentivirus containing GFP driven by the Pax7 promoter could be used to 








Aim 1: Future directions 
Experiments proposed in this aim provide detailed phenotypic analysis of defects 
associated with 343delT in skeletal muscle. These studies lay the groundwork for future 
examination of protein aggregates through cell fractionation coupled with proteomics via mass 
spectrometry. Components lost from the cytoplasm into the aggregates could be identified and 
their rescue tested for amelioration of phenotypes. Additionally, factors that upregulate autophagy 
(Hochfeld et al., 2013) and compounds that induce activation of the master regulator of heat 
shock gene expression, HSF-1 (Calamini et al., 2012) could also be examined for their ability to 
mitigate aggregation and additional phenotypes. Future work may also focus on better defining 
mechanisms of action as well as defining tissue-specific effects. iPSCs can be readily 
differentiated into cardiomyocytes, which, as of now, in the patient appear to be asymptomatic for 
cardiac manifestations. These studies may elucidate why skeletal but not cardiac muscle is 
impacted and may be predictive of future cardiac involvement in the patient.  
 
Specific Aim 2: Modeling Disease-causing HSPB5 343delT-Associated 
Congenital Myopathy Using Genetically Engineered Rats 
Aim 2: In vivo rat model generation 
Rationale.  iPSC model system has its limitations for the study of HSPB5-associated 
myopathies (Limphong et al., 2013; Mitzelfelt et al., 2016). Establishment of critical models with 
translational relevance in humans is crucial to pursue mechanisms of disease pathogenesis (i.e., 
progenitor cell biology, mitochondrial biology, calcium homeostasis) that might impact treatment 
outcomes in affected patients. Specifically, proinflammatory and extracellular matrix pathways 
also contribute to muscle integrity and function in both health and disease. Accordingly, a rat 
model of HSPB5 343delT will complement the studies outlined in Aim 1 providing an in vivo 
model system. Genetically engineered rats are a larger rodent model, compared with mice, which 





during development and throughout the organism’s lifespan. This advantage may also expose 
cardiac phenotypes not yet observed in the patient due to maturity, which has added benefit of 
potential preventative care. Finally, the use of a rat model allows for the opportunity to test 
methods of treatment for similarly affected patients. While preliminary work could be conducted 
in 343delT and control iSKMs, further testing in a whole model organism is an essential next step 
to validate any therapeutic intervention before clinical applications. This is an ambitious aim with 
considerable risk due to the inherent challenges of developing a transgenic rat model; however, 
the ability to study 343delT with an in vivo system will provide an invaluable tool to advance the 
understanding and treatment of MFM. 
Methods.  A rat strain containing the 343delT patient mutation will be produced by the 
transgenic core. Homozygous and heterozygous 343delT rats will be generated to model both the 
affected patient and the unaffected parents, respectively. Verification of the intended truncation of 
HSPB5 will be conducted using western blotting, qRT-PCR, and immunohistochemistry 
comparing with wildtype rats from the same genetic background. While there was no evidence of 
lethality observed in the DKO mouse (Brady et al., 2001), viability of the proposed strains will be 
assessed via surveying the genotypes of the neonate pups and determining the survival rate of 
each genotypes throughout the duration of the study.  
Axial muscles surrounding the spine, the muscles of the forelimb, and the muscles of the 
hind limb of 343delT homozygous rats could exhibit the most severe phenotype (Brady et al., 
2001) compared with either heterozygous 343delT or controls rats. The 343delT patient also 
demonstrates respiratory distress, thus, the diaphragm will be examined for evidence of myopathy 
(Forrest et al., 2011). Standard muscle fiber cross sectional size and fibrosis will be quantified 
and compared across all rat strains using H&E and trichrome staining as previously described 
(Brady et al., 2001). However, both electron microscopy and immunohistochemistry, including 
the more reliable Evans blue exclusion assay, will be used to evaluate myocyte damage and 





blotting and immunofluorescence studies. Evidence of adverse outcomes will include quantitative 
biochemical analysis of skeletal muscle damage (e.g., creatine kinase MM, p62, desmin, and 
myotilin) (Goicoechea et al., 2008), aggregation (HSPB5 and desmin), apoptosis (Fas and p53), 
extracellular matrix proteins (e.g, MMP9) and fibrosis (e,g., hydroxyproline assay) observed 
between 343delT vs controls as previously described (Forrest et al., 2011; Lee et al., 2001). qRT-
PCR will be performed to determine whether either increases or decreases of selected biomarkers 
are due to enhanced transcription or selective protein degradation. If time permits, preliminary 
studies will assess mitochondrial biogenesis such as PGC-1α content, cytochrome-c, ETC 
complexes I-V, citrate synthase, antioxidative pathways including SOD2, GPX and several 
markers of inflammation (NFkB) and immune cell infiltration (e.g., MPO staining, CD45) of 
homozygous 343delT compared with controls. Whole body strength will be determined by using 
a wire screen holding test as previously described (Carlson et al., 2010). 
The 343delT patient exhibits severe muscle stiffness and weakness. Therefore, functional 
assessment of skeletal myopathy in all rat strains listed will be conducted in collaboration with 
Dr. Robert Fitts as previously described (Fitts et al., 2010). Briefly, bundles of fibers will be 
prepared from the primarily slow soleus and fast gastrocnemius muscles, the bundles chemically 
skinned, and stored at -20°C. On the day of an experiment, single fibers will be isolated, mounted 
between a force transducer and length motor, and sarcomere length set at 2.5 µ. Short, rapid 
length perturbations (0.05% fiber length at 1.5 KHz) will then be applied in relaxing (pCa 9.0) 
and activating (pCa 4.5) solution and fiber stiffness determined from the resulting change in force 
in response to the length step (Fitts et al., 2010). Passive fiber stiffness will be determined by 
measuring the length-tension relationship in relaxing solution at sarcomere lengths from 1.9 -3.1 
µ. Following the stiffness measurements, fiber strength will be assessed by determining peak 
force, rate of tension development (dp/dt), velocity and power (Fitts et al., 2010). 
Expected results and interpretation.  Production of homozygous 343delT rat strains are 





343delT rat should reveal increased muscle degeneration when compared to the wildtype rats. 
Expected phenotypes include: aggregates containing HSPB5, alterations in muscle fiber size, 
increased fibrosis, elevated apoptosis, increased expression of myofibrillar degeneration markers, 
and ultrastructural evidence of degenerative changes. Functionally, the homozygous 343delT rats 
should demonstrate decreased muscle strength similar to the affected patient. In the 343delT 
fibers compared to control fibers, titin is expected to be altered to increase the passive tension 
(i.e., stiffness) but have less effect on stiffness measured in activated fibers as that reflects the 
number of active cross-bridges. Altered stiffness in activated fibers would suggest that either the 
cross-bridge number was altered and/or that other factors such as changes in myosin binding 
protein C altered stiffness. Additionally, the heterozygous 343delT rats are expected to have a 
phenotype similar to that of the wildtype rats, which would model the asymptomatic parents of 
the 343delT patient. 
Possible pitfalls and alternative approaches.  If the 343delT rats do not demonstrate 
degeneration of muscle cells, animals will be physically stressed to elucidate a phenotype. 
Exercise stress will be administered via swimming or treadmill exercise as previously described 
(Handschin et al., 2007; Samy et al., 2015). Increased evidence of muscle degradation is expected 
in response to physical stress. 
 
Aim 2: Future directions 
The generation of a 343delT rat would allow for significant studies investigating the role 
of HSPB5 in myogenic progenitor cells and potential treatments for MFM patients especially 
with early-onset and age-dependent damaged tissues. The 343delT model would be an invaluable 
tool to further study the role of HSPB5 in muscle development and regeneration. Moreover, a 
whole organism model of the 343delT patient would provide a platform to assess effective 
therapeutic interventions including drug testing and is a prerequisite for any future gene/cell-
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 Technological advances with stem cells and genome editing have revolutionized methods 
for studying human disease. This dissertation presented an example utilizing these techniques for 
the study of a mutant chaperone, HSPB5 343delT, and its association with myopathy. It also 
attempts to address a technical hurdle currently faced by the genome editing field- low editing 
efficiencies in iPSCs- through presentation of a novel genome editing strategy called cotargeting 
with selection (CTS). Altogether, this work is at the forefront of new technological capabilities 
that has and will no doubt continue to provide mechanistic insights into disease, generate 
platforms for drug screening, and, perhaps, translates into regenerative cell therapies in humans. 
